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ABSTRACT OF DISSERTATION

INCREASED OXIDATIVE DAMAGE TO DNA AND THE EFFECTS ON
MITOCHONDRIAL PROTEIN IN ALZHEIMER’S DISEASE

Alzheimer’s disease (AD) is a progressive, irreversible, neurodegenerative
disease. The key to understanding AD is to elucidate the pathogenesis of neuron
degeneration in specific brain regions.
We hypothesize that there is increased DNA oxidation in AD brain compared to
age-matched control subjects, especially in mitochondrial DNA (mtDNA), and that
the changes in DNA bases will affect protein expression in mitochondria and
contribute to neurodegeneration in AD. To test this hypothesis:
1) We quantified multiple oxidized bases in nuclear DNA (nDNA) and mtDNA
of frontal, parietal, and temporal lobes and cerebellum from late-stage AD (LAD),
mild cognitive impairment (MCI), and age-matched control subjects using gas
chromatography/mass spectrometry with selective ion monitoring (GC/MS-SIM).
Also, we quantified oxidized DNA bases in cortex of APP/PS1 transgenic mice. (a)
nDNA and mtDNA were extracted from eight LAD and eight control subjects. We
found levels of multiple oxidized bases were significantly higher in frontal, parietal,
and temporal lobes and that mtDNA had approximately 10-fold higher levels of
oxidized bases than nDNA. Eight-hydroxyguanine was approximately 10-fold
higher than other oxidized base adducts in both LAD and control subjects. These
results suggest that oxidative damage to mtDNA may contribute to the
neurodegeneration of AD. (b) Mild Cognitive Impairment (MCI), the phase between
normal aging and early dementia, is a common problem in the elderly with many
subjects going on to develop AD. Results from eight amnestic MCI and six control
subjects suggest oxidative damage to DNA occurs in the earliest detectable phase of
AD. (c) Analysis of nDNA from the cortex of four groups (3m, 6m, 9m, 12m) of
APP/PS1 and wild type mice showed elevations of 8-hydroxyguanine in 12 month old
APP/PS1 mice.
2) To analyze mitochondrial protein changes in LAD, 2D gels were run to
separate proteins and MALDI-TOF mass spectrometry was used to identify proteins.

Five mitochondrial proteins were significantly decreased in LAD. This proteomic
study provides a proteome map of mitochondria in LAD brain and an insight into the
pathogenesis of neuron degeneration in Alzheimer’s disease.
Key words: Alzheimer’s disease, Mild Cognitive Impairment, Nuclear and
mitochondrial DNA oxidation, Proteomics, Mass Spectrometry
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CHAPTER ONE
Introduction

1.1 Alzheimer’s disease

1.1.1 Overview of Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive, irreversible, neurodegenerative disorder.
In 1907, Alois Alzheimer, a German psychiatrist and neuropathologist, published a paper
that described a 51-year-old woman with a 4 ½ year course of progressive dementia
which subsequently bears his name (Alzheimer 1907). The patient died in a completely
demented state. Autopsy revealed an atrophic brain with cortical neuron loss and the
presence of silver-positive intracellular tangled bundles of fibers (now called
neurofibrillary tangles (NFTs)) and extracellular deposits (now called senile plaques
(SPs)), two main hallmark pathological features of AD.
AD is the most common form of dementia in the elderly. Current data suggest
AD affects 4-5 million people in the US and 20-30 million people worldwide with a
prevalence of 3% for the persons 65-74 years old, 18.8% for those 75-84 years old, and
47.2% for those over 85 years old (Katzman 1976; Markesbery and Carney 1999; Martin
1999). Without efficient preventative methods, it is estimated that by 2050 ~45 million
individuals worldwide could develop this disorder with increasing life span (NIA 1995;
Selkoe and Schenk 2003).

1.1.2

Clinical characteristics of AD
AD is characterized by memory loss, behavior changes, and impaired cognitive

ability.

At the very early stage, the only symptom is mild forgetfulness. Patients can

not recall the names of recent activities or events. Most people with mild forgetfulness
likely do not develop AD. It is easily confused with normal aging forgetfulness, which is
not progressive (Sclan and Kanowski 2001).

As the disease goes on, progressive

worsening of memory is more noticeable. AD patients have trouble learning, speaking or
thinking, and cannot carry out daily activities, such as combing their hair, brushing their

1

teeth, or recognizing familiar people around them. At later stages of AD, patients can
become aggressive or wander away from home (Selkoe and Schenk 2003).

1.1.3

Pathological features in AD
Two hallmark pathological features of AD are the presence of neurofibrillary

tangles (Figure 1-1) and senile plaques (Figure 1-2). NFTs are intracellular and are
composed of paired helical filaments (PHF), which consist of hyperphosphorylated tau, a
neuron-specific phosphoprotein that is the major constituent of neuronal microtubules
and predominantly located in the axon (Trojanowski and Lee 1995). NFTs are generally
present in neurons of the cerebral cortex and are mainly found in temporal lobe structures
of the AD brain, such as hippocampus and amygadala (Pappolla et al. 1992; Wang et al.
2006).
Senile plaques are extracellular deposits composed of β–amyloid (Aβ)
polypeptides (39 to mainly 42 amino acids) derived from the amyloid precursor protein
(APP), a transmembrane glycoprotein precursor, synthesized in endoplasmic reticulum,
and transferred to secretory vesicles and cell surface through Golgi apparatus
(Weidemann et al. 1989). APP is cleaved by β-secretase to release N- terminal Aβ-42. γsecretase cleaves APP to release the C- terminal of Aβ-42. Due to the different cleavage
sites of β-secretase, Aβ-40 is also produced (Citron et al. 1996).

These peptides

aggregate easily and form plaques. Traces of transition metals, such as copper, zinc, and
iron, may accelerate this aggregation (Lovell et al. 1998). However, Aβ-40 is more
soluble and less neurotoxic than Aβ-42. Numerous studies show that Aβ-42 may play an
important role in the pathogenesis of AD (Citron et al. 1996; Selkoe and Schenk 2003).
Senile plaques are present in the brain in normal aging and Alzheimer’s disease, although
the AD brain has higher numbers of senile plaques compared to normal aging.
Besides NFTs and SPs, synapse loss and neuron dysfunction occur in AD.
Histological examination of AD brain shows pyramidal neuron loss in the hippocampus,
which may be caused by accumulated amyloid plaques (DeKosky and Scheff 1990;
Scheff and Price 1993; Kril et al. 2002; Kril et al. 2004; Schmitz et al. 2004; Simard et al.
2006). Pyramidal neurons are the primary cell type in cortex and hippocampus.

2

Figure 1-1. Schematic of the formation of neurofibrillary tangles in neuron
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Figure 1-2. Formation of senile plaques from cleavage of APP by β and γ-secretases
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Pyramidal neurons are composed of a pyramid-shaped cell body, a tree-like dendrite, and
axons. In addition, glia function as supporting cells in CNS. Previous studies show more
than half of large pyramidal neurons are damaged in the late stage AD in prefrontal
cortex and hippocampal CA1 region (West et al. 1994; Gomez-Isla et al. 1997; Bussiere
et al. 2003).

1.1.4 Risk factors of AD
The cause of AD is not fully understood. It probably is not a single cause, but a
consequence of several factors. These risk factors may interact with each other and affect
each person differently. Age is the most well known factor in AD. The number of people
with AD doubles every five years beyond age 65 (Evans et al. 1989; Floyd 1999).
Genetic factors (Henderson 1986), education, diet, environment (Zhang et al.
1990; Zawia and Basha 2005), and head injury (Heyman et al. 1984; French et al. 1985;
Sullivan et al. 1987; Borenstein et al. 2006) also play important roles in the development
of AD. Early-onset familial AD (FAD), a rare form of AD that usually occurs before age
60, is associated with several genetic mutations, including mutations of APP, Presenilin 1
(PS1) and Presenilin 2 (PS2) (Hardy 1997). Presenilins are transmembrane proteins with
six to nine transmembrane domains (Sherrington et al. 1995; Li and Greenwald 1996).
Studies show that PS1 and PS2 mutations alter APP processing in favor of Aβ production
(Borchelt et al. 1996; Scheuner et al. 1996). Presenilins are also substrates for a caspase3 family, and mutations in presenilins may make cells vulnerable to apoptotic cell death
(Kim et al. 1997; De Strooper et al. 1998).
However, the more common form of AD known as late-onset accounts for 9095% of total AD cases (Harman 2006). Apolipoprotein ε4 (ApoE4) is the only risk gene
identified so far for late-onset AD (Travis 1993; Markesbery 1997; Selkoe 1999). ApoE
is encoded by a gene on chromosome 19 and has three isoforms: ε2, ε3, and ε4. The risk
of AD increases three fold with one ε4 allele and eight fold with two ε4 alleles compared
to non-Apo ε4 carriers (Strittmatter et al. 1993; Evans et al. 1997).
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1.2 Mild Cognitive Impairment
Recent emphasis in adult dementing disorders is on early detection with the hope
of early treatment to slow disease progression. Mild Cognitive Impairment (MCI) is
generally considered to be the transitional zone between normal aging and early
dementing disorders, especially AD (DeCarli et al. 2001; DeCarli 2003; Wolf et al. 2004).
In general, most MCI subjects eventually convert to AD or other dementias with ~15% of
MCI subjects converting to AD per year (DeCarli 2003). Several studies of MCI show
elevated levels of tau (Okamura et al. 2002), Aβ (Andreasen et al. 1999), and
isoprostanes (Pratico et al. 2002) in ventricular cerebrospinal fluid (CSF), and more
recently significant elevations of DNA damage in peripheral leukocytes of MCI and AD
(Migliore et al. 2005). Additionally, several gene mutations associated with AD have
been observed in subjects with MCI including mutations in apolipoprotein E, PS1, and
APP (de Leon et al. 2001; Traykov et al. 2002; Lopez et al. 2003; Nacmias et al. 2004).

1.3 APP/PS1 transgenic mice
Although the majority of AD cases are sporadic, ~ 5% of cases, are linked to
specific mutant genes that encode the amyloid precursor protein (APP) or the presenilins
(PS1 or PS2) (Selkoe 2001; Selkoe and Schenk 2003; Esposito et al. 2004).
APP is encoded by a gene on chromosome 21, which can be cleaved by β- and γsecretases to produce amyloid-β peptides (Aβ) mainly containing Aβ40 and Aβ42 (Haass
and Selkoe 1993; Xu et al. 1997; Storey and Cappai 1999). Studies show that Aβ42
aggregates faster than Aβ40 and is more toxic to cultured neurons (Pike et al. 1993;
Roher et al. 1993; Watt et al. 1994; Lemere et al. 1996; Lovell et al. 1999b; Lovell et al.
2003). Why Aβ is neurotoxic is not clear. The possible reason is that Aβ may lead to the
production of free radicals which result the oxidation of protein, lipid, and DNA (Loo et
al. 1993; Hensley et al. 1994; Watt et al. 1994).
PS1 and PS2 are encoded by genes on chromosomes 14 and 1 respectively. More
than 50 mutations have been identified in PS1 gene, much more than those of in PS2
(Hardy 1997; Cruts et al. 1998).

Studies show increased Aβ42 production in PS1

transgenic mice (Duff et al. 1996). APP/PS1 mice have higher levels of Aβ42 compared
to single transgenic mice (Blanchard et al. 2003; Wirths et al. 2006).
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The amyloid cascade hypothesis suggests that Aβ processing and aggregation
may contribute to the pathogenesis of AD. Transgenic mouse models offer opportunities
to investigate the molecular mechanisms of Aβ production. APP transgenic mice show
early-onset deposition of Aβ in neocortex and hippocampus by 12 month of age (Games
et al. 1995; Hsiao et al. 1996; Chishti et al. 2001). Water maze tasks showed increased
age-related memory deficit in APP mice. Also, these mice show electrophysical
pathology and functional disruption in cortex and hippocampus (Hsiao et al. 1996;
Chapman et al. 1999; Stern et al. 2004). In the mouse model coexpressing APP and PS1,
the deposition of senile plaques is accelerated at early ages by 12 month of age and the
ratio of Aβ42/ Aβ40 was increased in brain (Borchelt et al. 1997; Holcomb et al. 1998;
Wengenack et al. 2000). Mutations in presenilins may accelerate the Aβ42 production by
altering APP processing (Duff et al. 1996).

1.4 Oxidative stress and AD

1.4.1

Free radical theory of aging
Current evidence indicates that oxidative stress is associated with aging. In 1956,

Denham Harman proposed the free radical theory of aging. It says that aging is due to the
cumulative damage from free radical mediated reactions. Reactive oxygen species (ROS)
are the byproducts of enzymatic redox chemistry. Traces of metal ions may catalyze
these reactions (Harman 1973; Smith et al. 2000a; Smith et al. 2000b; Harman 2003).

1.4.2 Mitochondria – power house of cells and source of ROS
Mitochondria are considered the “power house” of cells (Boyer et al. 1954), and
are composed of an outer membrane, inner membrane, and matrix (Figure 1-3). ATP
(adenosine triphosphate) is produced at the inner membrane through coupling of
oxidative phosphorylation with respiration (Boyer et al. 1954; Mitchell 1961). Five
enzyme complexes are involved in respiratory chain during energy production. While the
enzymes transfer electrons to oxygen in the final step, they pump protons out of the inner
membrane, establishing a proton gradient. It is this pH gradient that provides energy to
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drive ATP synthesis from ADP and inorganic phosphate (Boyer et al. 1954; Mitchell
1961; Wallace 1999; Jaroszewski et al. 2000; Stock et al. 2000; Eckert et al. 2003).
Mitochondria are then considered a “free radical factory” of the cell because of
potential electron leakage from the electron transport chain. Free radicals are atoms or
molecules with at least one unpaired electron in the outer shell and are chemically very
active (Sampson et al. 1998). In biological systems, free radicals mainly include reactive
oxygen species (ROS) and reactive nitrogen species (RNS) (Halfpenny and Robinson
1952; Smith et al. 1998). Oxidative phosphorylation is the major endogenous source of
ROS. During respiration, ~2% of the total oxygen consumed by the cell is converted into
.superoxide radical O2 by leaked electrons.

Cellular protective enzymes against

oxidative stress include Cu/Zn and Mn superoxide dismutases (SOD)

that convert

superoxide radical to hydrogen peroxide (H2O2) , which is either reduced to water or
.
more active hydroxyl radical OH in the presence of trace metals through the Fenton or

Haber-Weiss reaction (Figure 1-4) (Fenton 1894; Harbor and Weiss 1934).
Hydroxyl radicals plus H2O2 and singlet oxygen are the ROS we usually talk
about. Iron may play an important role in catalyzing and propagating these reactions
(Fenton 1894; Harbor and Weiss 1934; Xie et al. 1996; Lyras et al. 1997).

Studies have

indicated that there is increased iron in AD brain compared to controls (Ehmann et al.
1986). Another potential oxidant is nitric oxide (NO) which is produced in biological
reactions from the oxidation of L-arginine. By itself, NO is not very active, although it
can react with superoxide radical to from peroxynitrite ONOO-, a very reactive oxidant
that can oxidize DNA, protein and lipids (Marletta 1993; Hurshman and Marletta 2002).
Oxidative stress refers to the status when free radicals and their damaged products
are beyond the ability of repair systems (Kish et al. 1986; Imlay and Linn 1988; Beyer et
al. 1991). Mitochondria are the major source of endogenous free radicals in cells and
their DNA and protein may be more easily oxidized than nuclear DNA and protein
(Wallace 1992; Ames et al. 1993; Mecocci et al. 1993). Oxidative stress can decrease the
mitochondrial membrane potential, which induces cell death through apoptosis (Wadia et
al. 1998).

Mitochondrial DNA (mtDNA) tends to have higher mutation rates than

nuclear DNA (nDNA) because of the lack of histone protection and limited repair
mechanisms
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Figure 1-3. Diagram of a mitochondrion. Mitochondria are composed of an outer
membrane, inner membrane, and matrix.
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(Wallace 1992; Ames et al. 1993; Lovell et al. 2000b; Hashiguchi et al. 2004; Stuart et al.
2005). Mutations of mtDNA could cause functional consequences because mtDNA has
no noncoding sequences (Wallace 1992). Studies show that there is more than 10 times
the damage in mtDNA than is observed in nuclear DNA (Richter et al. 1988; Wang et al.
2005; Wang et al. 2006).

1.4.3

Oxidative stress and AD – protein oxidation and lipid peroxidation
Several lines of evidence indicate that oxidative damage plays an important role

in the pathogenesis in AD. Protein oxidation may affect neuron function by damaging
enzymes that are critical to neuron metabolism (Smith et al. 1991; Hensley et al. 1995;
Poon et al. 2004; Chen et al. 2005). Protein carbonyls have been used to measure
damaged protein (Gutteridge and Wilkins 1983; Smith et al. 1991; Youngman et al.
1992).

Previous studies show that protein carbonyls are increased in frontal lobe,

hippocampus, and parietal lobe in AD compared to control subjects (Smith et al. 1991;
Hensley et al. 1995). Studies show that nitrotyrosine is present in NFT in AD brain
(Smith et al. 1997).
Lipid peroxidation can cause structural membrane damage leading to cell death
and produce secondary bioreactive aldehydes, such as 4-hydroxy-2-nonenal (HNE) and
acrolein (Benedetti et al. 1980; Benedetti et al. 1986; Lovell et al. 1997; Bruce-Keller et
al. 1998; Markesbery and Lovell 1998; Lovell et al. 2000a, 2001). These two chemicals
may form adducts with DNA and protein, which can modify their normal functions. They
are both increased in the AD brain and are toxic to cultured neurons (Lovell et al. 1997;
Lovell et al. 2000a, 2001). Additionally, HNE is shown to be elevated in cerebrospinal
fluid (CSF) of AD subjects (Lovell et al. 1997). Studies also show that the concentration
of isoprostanes in the CSF of AD subjects is higher than in the controls (Montine et al.
1998; Musiek et al. 2004). Isoprostanes, a measure of lipid peroxidation, are produced by
non-enzymatic, free radical-catalyzed peroxidation from arachidonic acid (Morrow et al.
1992a; Morrow et al. 1992b; Milne et al. 2005).
Studies of antioxidants in AD show varied results. Several studies have shown
increased enzyme activities including Catalase, SOD, GSH-Px and GSSG-R, which
suggested that elevated enzyme activities reflect a compensatory response to increased
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ROS species (Lovell et al. 1995).

Some studies show that there is no significant

difference or reduced enzyme activity in AD brain (Richardson 1993; Marcus et al. 1998).
These inconsistent results suggest that the neuron death in AD brain may not be due to
the damages of antioxidant enzymes.

1.4.4

Oxidative stress and AD – DNA oxidation
ROS, especially hydroxyl radicals, can attack DNA bases, leading to more than

20 oxidized base adducts (Steenken 1989a; Cooke et al. 2003). As a consequence of
oxidation, DNA may have strand breaks, DNA-DNA and DNA-protein crosslinking, and
base modification (Davies 1995; Crawford et al. 2002). Oxidized DNA also may lead to
cell death by changing protein expression.
Several biomarkers of DNA damage have been quantified, including 8-hydroxy2’-deoxyguanosine (8-OHdG), the most useful of several damaged bases (Mecocci et al.
1993; Mecocci et al. 1994; Gabbita et al. 1998; Lovell et al. 1999a). Previous studies
show that there is more 8-OHdG in mtDNA than in nuclear DNA and there is a
significant increase in aged subjects compared to younger subjects.
The first step in DNA oxidation is to add hydroxyl radical to the double bond of
bases. The addition of .OH to the C5-C6 double bond of pyrimidine results in C5-OH or
C6-OH adducts (Steenken 1989b, c). The products following these two adducts depend
on the absence or presence of oxygen. For purines, the hydroxyl radical is added to C4,
C5, or C8 to form the purine-OH radicals. Among them, C8 is the most probable
addition position. For guanine-C4 adducts, the elimination of a hydroxyl group leads to
the guanine radical cation, which can react with 2’-deoxyribose in DNA causing DNA
strand breaks (Steenken 1989c). The guanine-C8 adducts can produce 8-hydoxyguanine
with one electron oxidation and produce 2, 6-diamino-4-hydoxy-5-formamidopyrimidine
(fapyguanine) with one electron reduction following the ring opening (Steenken 1989c;
Dizdaroglu et al. 2002) (Figure 1-6). There are more than 20 damaged bases already
described (Cooke et al. 2003). 8-hydroxyguanine has ~1% chance to mispair with
adenine resulting in G→T substitution (Cheng et al. 1992).

Previous studies show

increased levels of some oxidized bases in certain AD brain regions (Lyras et al. 1997;
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Gabbita et al. 1998). In our study, we are interested in the following six oxidized DNA
bases because they show higher levels compared to other DNA adducts. They are
8-hydroxyguanine, fapyguanine, 8-hydroxyadenine, 4,6-diamino-5-formamidopyrimidine
(fapyadenine), 5-hydroxycytosine, and 5-hydroxyuracil (Figure 1-5).

The detailed

mechanism of the production of these six oxidized bases is shown in Figure 1-6.

1.5 Methods to quantify DNA oxidation

1.5.1 Commonly used methods to detect DNA adducts
Oxidized DNA bases can be measured by various analytical methods. The two
most commonly used methods are high-performance liquid chromatography with
electrochemical detection (HPLC/ECD), and gas chromatography / mass spectrometry
with selective ion monitoring (GC/MS-SIM) (Dizdaroglu et al. 2002). In HPLC/ECD,
DNA is enzymically digested into 2’-deoxyribonucleosides before HPLC analysis, while
for GC/MS-SIM, acidic hydrolysis is carried out to yield intact and damaged bases that
are further derivatized (Herbert et al. 1996; Collins et al. 1997). Artifactual oxidation of
DNA bases could be induced during derivatization for GC/MS. Unlike acidic hydrolysis,
enzymic hydrolysis only cleaves the damaged nucleosides from DNA backbone.
Enzymic hydrolysis method does not induce artifact in the analysis (Dizdaroglu 1998).
However, HPLC/ECD can not provide spectroscopic support for structural identification
of adducts. Studies also show that acid hydrolysis does not cause any artifacts once the
DNA sample is processed under proper experimental conditions (Dizdaroglu 1998).
Because enzymes are significantly more costly than formic acid and take a longer time,
acid hydrolysis can replace enzymic digestion.
Liquid chromatography / mass spectrometry (LC/MS) and liquid chromatography
/tandem mass spectrometry (LC/MS/MS) are also used to quantify DNA adducts
(Serrano et al. 1996; Ravanat et al. 1998; Jaruga et al. 2002; Liu et al. 2005; Van den
Driessche et al. 2005). However, LC/MS and LC/MS/MS are less sensitive compared to
GC/MS-SIM (Dizdaroglu et al. 2002; Jaruga et al. 2002). The sensitivity of GC/MS-SIM
is 1-2 fmol for 8-hydroxyguanosine, whereas the sensitivity of LC/MS is ~30 fmol and
LC/MS/MS is 10-20 fmol (Dizdaroglu et al. 2001; Jaruga et al. 2002). Because of the
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Figure 1-5. Structures of oxidized DNA bases in our study
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Figure 1-6. Formation of oxidized bases from guanine, adenine, and cytosine
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high sensitivity of GC/MS-SIM, this method needs less DNA for analysis. GC/MS-SIM
can provide accurate quantification and identification with high selectivity and sensitivity.
Using GC/MS, hydrolysates after formic acid are derivatized with silylating reagents
containing trimethylsilyl (TMS) groups, such as N,O-Bis(trimethylsilyl)acetamide (BSA)
and N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA).

During derivatization, TMS

groups will replace the H- in OH, NH, and SH groups. The derivatives are generally less
polar, more volatile, and more thermally stable (Halliwell and Dizdaroglu 1992). In
selective ion monitoring mode, GC/MS can analyze a wide range of bases in a single run
with high sensitivity and selectivity of detection (Halliwell and Dizdaroglu 1992;
Dizdaroglu et al. 2002). Stable isotope-labeled internal standards with the exact same
chemical and physical properties as analytes are used for quantification of the damaged
bases based on the ratio of the peak areas of base adducts versus internal standards.

1.5.2 Principles of GC/MS
GC/MS is one of the most commonly used techniques to analyze volatile organic
chemicals. GC/MS is composed of a component for chemical mixture separation (gas
chromatograph), a sensitive and qualitative detector (mass spectrometer), and a data
collection system (Figure 1-7) (Santos and Galceran 2003). The carrier gas, such as
nitrogen, helium, or hydrogen, must be chemically inert to analytes (Parcher 1983;
Blumberg 1997). The choice of carrier gas depends on the detector and analytes. In
order to shorten analysis time, hydrogen or helium is usually used because of their low
viscosity. The carrier gas must be highly pure in order to reduce deterioration of the
stationary phase and to limit potential contamination. A constant flow of carrier gas is
always desirable to get a constant retention time.
For optimum efficiency and high resolution, a microsyringe is commonly used to
inject microliter samples through a rubber septum into a heated chamber with a higher
temperature by 20°C to 40°C than column. Once the sample is introduced, it is vaporized
rapidly and swept into the column by the carrier gas (Schomburg et al. 1981; Lieshout et
al. 1998). For capillary GC, split or splitless injections are used. In the split mode, most
of the sample exits with most of the sample lost through the split cutlet. Split ratios vary
from 10:1 to 500:1 (Bayer 1986). Because most of the sample in the split injection mode

16

is wasted, it is generally not suitable for ultra-trace analysis. In the splitless mode, the
residence time of sample in the injection port is longer because of the relatively larger
sample volume and the lower velocity of carrier gas compared to split injection
(Schomburg et al. 1981; Matovská and Lehotay 2003).
Packed or capillary (open tubular) columns are usually used, while capillary
columns are more efficient (Grob 1982; Gübitz and Schmid 2000). Column tubing must
be chemically inert and thermally stable. Fused silica open tubular column is a new type
of wall coated capillary column with much thinner walls than the other glass capillary
columns, and provides high sensitivity and reproducibility. The polyimide coating makes
the fused silica columns flexible and inert. However, micro cracks might occur in the
fused silica because of the differences in thermal expansion of silica and aluminum
coating

(Michalske and Freiman 1982).

Usually, efficiency increases but sample

capacity decreases as the internal diameter or film thickness decreases. Column length is
another factor that affects resolution. Longer columns improve resolution but increase
analysis time (Ettre and March 1974; Matovská and Lehotay 2003).
Temperature control on columns is very important for good reproducibility.
Retention time increases as column temperature decreases.

In order to get good

separation, a temperature slightly above the boiling points of analytes is used for analysis.
For the samples with a wide range of boiling points, a temperature program is usually
used to avoid poor resolution or long analysis time caused by isothermal analysis
(Lieshout et al. 1998).
GC detectors are classified into two categories. One is concentration-sensitive
and independent of mass flow of analytes, such as thermal conductivity detectors (TCD)
and electron capture detectors (ECD). The other type is a mass-sensitive detector, such
as MS and flame ionization detector (FID) (Halász 1964). Once separated analytes flow
through the interface between the GC and the MS, they enter the ionization chamber of
MS. The interface is maintained at high vacuum (< 10-2 Pa) so that no molecular
reactions occur. In the MS, electron impact or chemical ionization is used for ion
production.

Molecular ions (M+) are separated based on different mass/charge ratios by

mass analyzer, such as quadrupole analyzer, ion trap ， etc.

Because of the high

sensitivity, a quadrupole analyzer is generally used in GC/MS. The peaks are recorded
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Figure 1-7. Diagram of gas chromatography – mass spectrometry
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by a detector and a computer processes the data and converts the electrical signal into a
spectrum. The mass spectrum indicates the peaks of molecular ion and other fragments,
and the abundances of these ions (Matovská and Lehotay 2003).
Mass spectrometers may be operated in various scanning modes, including full scan
and selected ion monitoring (SIM). Analysis in the full scan mode monitors all ions over
the full cycle. However, sometimes, only a few selected ions are of interest in an analysis.
SIM is used in this case with a higher sensitivity compared to full scan mode, because the
selected ions are monitored for a greater portion of the scan time. Detection limits
decrease as the number of ions increases (Vékey 2001).

1.6 Proteomics

1.6.1

Background of proteomics
The proteome, the basic sum of “protein” and “genome”, is used to describe the

entire complement of proteins in a biological system (Wasinger et al. 1995). Proteomics
is the field involved with the characterization, quantification, and identification of global
proteins in cells, tissue, or organism (Wasinger et al. 1995; Anderson and Anderson 1996;
Wilkins et al. 1996; Peng and Gygi 2001; Pedersen et al. 2003).

Proteomics was

introduced in the 1970s with two dimensional (2D) electrophoresis (O'Farrell 1975;
Scheele 1975). Although many proteins were separated at that time, they could not be
fully identified because of the limited sequencing techniques. Edman degradation, a
method of sequencing amino acids in a small peptide for identification of protein, was a
big breakthrough in protein sequencing (Edman 1949).

The first protein mapping

database was established in 1987 with the methods of 2D electrophoresis and Edman
degradation (Celis et al. 1987). However, Edman degradation is low-throughout process
and can not sequence peptides over 50-60 residues. One milestone in proteomics was the
introduction of mass spectrometry into the analysis of biological molecules, which
provides an accurate, sensitive, and high throughput method for protein identification
(Andersen and Mann 2000; Pandey and Mann 2000).
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1.6.2 Synthesis of mitochondrial proteins
The human mitochondrial genome is much smaller (16.6 kbp) than the nuclear
genome (3.3 billion bp). mtDNA encode 13 subunits of complexes involved in oxidative
phosphorylation (Wallace 1999) and the necessary RNA machinery (2 rRNAs and 22
tRNAs) (Taylor and Turnbull 2005). The remaining mitochondrial proteins are encoded
by nuclear DNA, synthesized at cytoplasmic ribosomes, and transported into the
mitochondrial matrix (Figure 1-8). Mitochondrial protein precursors with an N- terminal
extension as a targeting signal are recognized by a receptor on the mitochondrial surface.
The cleavable signal normally consists of a ~20-60 amino acids residue and an
intramitochondrial sorting signal (von Heijne et al. 1989). These precursor proteins are
transported by Translocase complexes in the Outer and Inner Membrane (TOM and TIM)
(Pfanner et al. 1996). Electrochemical potential and ATP hydrolysis are required during
the translocation through membranes (Schleyer et al. 1982; Horst et al. 1997). Then the
presequence signal is cleaved off by mitochondrial processing peptidase (MPP) localized
in matrix (Schatz 1996; Gakh et al. 2002). This non-native protein is refolded in the
matrix and becomes functional in mitochondrial matrix. Unlike proteins in matrix, most
outer membrane proteins and carriers proteins on inner membrane do not have a
cleavable signal.

1.6.3 Protein separation and isolation
The most efficient way to separate a protein mixture is polyacrylamide gel
electrophoresis. In one dimensional electrophoresis, protein mixtures are separated based
on molecular weight after denaturation in sodium dodecyl sulfate (SDS). SDS makes
proteins negatively charged and run in the electric field in a polyacrylamide gel (Laemmli
1970).
For a whole cell lysate or a very complex protein mixture, 2D electrophoresis is
generally used for separation (Figure 1-9). The gel separates proteins based on different
isoelectric points (PI) in the first dimension and molecular weight in the second
dimension. One single gel can separate complex mixtures of thousands of proteins. One
application of 2D electrophoresis is to map proteins from cells or tissues and compare the
protein expression between experimental groups.
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Figure 1-8. Diagram of formation of mitochondrial protein
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Several techniques have been developed to resolve the problem of reproductivity
in 2D electrophoresis over the years (Anderson and Anderson 1996; Celis and Gromov
1999). The introduction of immobilized pH gradient (IPG) strips to replace tube gels was
one of the biggest improvements which increased reproducibility between samples
(Bjellqvist et al. 1993; Gorg et al. 2000). In isoelectric focusing (IEF), a high voltage is
applied to the ends of strips consisting of polymerized acrylamide gel on a plastic base.
After the IEF is complete, the strip is equilibrated with thiol reductant and denaturing
reagents and applied to the second dimensional SDS polyacrylamide gel electrophoresis
(SDS-PAGE). The other exciting improvement is termed differential gel electrophoresis,
which uses different fluorescent dyes to tag different protein samples.

Those two

samples are run on the same gel and create two images using different fluorescent
wavelengths (Unlu et al. 1997).
After isoelectric focusing and SDS-PAGE, a protein spot map is visualized with a
proper staining method. Most often, each spot represents a unique protein. The spots of
interest are cut out followed by trypsin in-gel digestion. The peptide digest is analyzed
using mass spectrometry. The experimental mass spectrum is input into a database
containing theoretical protein sequences. Based on the peptide mass fingerprints specific
to one protein, the protein is identified (Henzel et al. 1993; Borodovsky et al. 2002;
Butterfield et al. 2003; Butterfield and Castegna 2003; Weiler et al. 2003).
To visualize and quantify protein spots, chemical staining such as Coomassie blue
G-250/R-250, SYPRO Ruby, fluorescence, and silver are generally used on 2D gels
(Urwin and Jackson 1993; Matsui et al. 1999; Berggren et al. 2000). The problem is that
low level proteins cannot be detected using this method.

Antibody-based detection

methods are more specific and more sensitive than the usual chemical stains, although
quantification is more difficult because of a limited dynamic range (Jarvik and Telmer
1998).
Although a lot of effort has been devoted to resolve the problems in 2D
electrophoresis, it is still a labor and time consuming process. Also, membrane proteins
are difficult to detect because of low solubility.
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Figure 1-9. Diagram of proteomics with 2-dimensional gel electrophoresis and protein
identification based on peptide mass fingerprint
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1.6.4 Protein identification and quantification
Two major methods for protein identification are Edman degradation and mass
spectrometry. Edman degradation was developed by Pehr Edman for identification of
proteins and was a major breakthrough in protein sequencing (Edman 1949). The Nterminal amino acids are cleaved off the peptide without breaking other peptide bonds.
The cleaved amino acids are identified through formation of phenylthiohydantoin –
amino acid derivatives followed by chromatography or electrophoresis. The procedure is
repeated to identify the next amino acid. Peptides longer than 50 – 70 amino acids can
not be analyzed reliably by Edman degradation. Long peptides need to be broken up into
small peptides and be sequenced individually (Aebersold et al. 1988; Alms et al. 1999).
One of the big limitations of Edman degradation is that it does not work if the N-terminal
amino acid is chemically modified or concealed in the body of protein.
Mass spectrometry has been widely used in recent years for rapid protein
identification. In proteomics, the protein is introduced into the MS in the form of
peptides after protease digestion. Electrospray ionization (ESI) and matrix-assisted laser
desorption/ionization (MALDI) are two most commonly used methods to ionize peptides.
In ESI, fine liquid charged droplets are generated after the liquid sample flows through a
microcapillary column into an electronic field (Wilm and Mann 1996; Wilm 2000). As
the solvent evaporates, the charged droplet is broken into tiny droplets as the charge
reaches a critical point. ESI is a kind of soft ionization method because it does not break
the molecules (Fenn et al. 1989). Nanospray ionization was introduced to analyze low
abundance proteins at the femtomole level (Wilm et al. 1996; McCormack et al. 1997).
Liquid chromatography (LC) has been used to as an automatic sample introduction
method recently to replace manual loading methods (McCormack et al. 1997).
MALDI is a laser-based soft ionization method to promote the formation of
molecular ions (Karas and Hillenkamp 1988). The analytes are spotted on metal plates
with matrix, usually an aromatic acid with chromophore which strongly absorbs laser
energy, such as α-cyano-4-hydroxycinnamic acid.

The selection of matrix is very

important for generation of a good mass spectrum. Matrix materials must be chemically
inert, stable in high vacuum condition, and easy to evaporate. As the solvent evaporates,
a crystal spot is formed. However, it can not used to analyze peptides bigger than 10
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KDa. Koichi Tanaka developed MALDI to be used in the whole range of biological
macromolecules in 1988, which allowed him to share the 2002 Noble prize for chemistry
with John Fenn.
Once the peptides ions are generated, they are analyzed based on different
mass/charge ratios (m/z). The most commonly used mass analyzers are quadrupole, time
of flight (TOF), and ion trap mass analyzers. The quadrupole is composed of four
parallel metal rods. On one pair, a direct current voltage is applied, while a radio
frequency voltage is applied to the other pair. Based on the ratio of given voltages, only
ions with a select range of m/z pass through the rods and reach the detector (Miller and
Denton 1986; Burlingame et al. 1998). A series of triple quadrupoles can be used in
analysis, in which the first and third quadrupoles work as mass filter, and the second one
works as a collision cell.
Another commonly used analyzer is TOF, which measures ions based on the time
taken to reach detectors through a flight tube. After the ions are accelerated by an
electrical field, they have the same kinetic energy (KE):
1 ⎛d ⎞
KE = zeV = .m.⎜ ⎟
2 ⎝t⎠

2

↓
t = d.

1 m
.
2eV z

Where m is the mass of the ion; z is the charge; V is the acceleration voltage; d is
the length of the flight tube & t is the flight time. The velocity of ions depends on their
mass/charge ratio. They will fly through the tube at different speeds because they have
the same kinetic energy and same charge (Yates 1998). Reflective TOF has an ion mirror
which can reflect ions back to reach a detector. It increases the resolution through
increasing flight length of ions.
Ion trap analyzer has three electrodes, a ring electrode and two hemispherical
electrodes located on two sides. It selectively ejects trapped ions through changing
voltages on electrodes (Cooks et al. 1991; Yates 1998).

25

1.6.5 Database searching
Once mass spectra are generated, database search engines, such as Mascot,
provide a speedy way to identify proteins, using the peptide mass fingerprint (PMF) to
identify proteins from primary sequence database (James et al. 1993; Yates et al. 1993;
Perkins et al. 1999).

In PMF, the experimental masses of peptides obtained from

proteolytic enzyme digestion are input into the database and are compared with
theoretical masses of peptides. Based on the overlap of experimental and calculated
masses, a Mowse score is used to describe the match. Rather than the number of the
matched peptides, Mowse scores count the match on a probability-based scoring (10*log10P) (Pappin et al. 1993). However, in PMF, it is hard to identify big genomes
because of the peptide mass redundancy.

Posttranslational modification of proteins

causes another problem in PMF identification, which results in no match in the calculated
database. Because of the complexity of peptides, this method cannot be used in the
identification of protein mixtures (Clauser et al. 1999).
There are several database search methods available for identification of protein
mixtures, such as amino acid sequence database searching (Mann and Wilm 1994; Wilm
et al. 1996), De novo peptide sequence information (Mackey et al. 2002), and
uninterpreted MS/MS data searching (Yates et al. 1995; Perkins et al. 1999). Amino acid
sequence searching is more specific than PMF. In this method, a partial amino acid
sequence is determined by MS/MS spectra. Combined with the mass of parent peptide
and masses of the peptides on each end, the unknown peptide is matched with the
theoretical peptide sequence in the database (Mann and Wilm 1994; Wilm et al. 1996).
De novo peptide sequence databases can provide both sequence information of DNA and
protein. It can be used in the organisms that have no well-annotated databases (Mackey
et al. 2002).

The most commonly used method to interpret MS/MS spectra is

uninterpreted MS/MS data searching, such as Mascot, or SEQUEST (Yates et al. 1995;
Perkins et al. 1999). Although several improvements have been made in proteomics,
especially in protein mixture identification, it is still a big challenge to identify the lowabundance proteins and highly modified proteins.
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1.7 Statements of research projects

1.7.1

Increased oxidative damage in nuclear and mitochondrial DNA in
Alzheimer’s disease
As mentioned above, oxidative stress plays an important role in the development

of AD. ROS can attack DNA bases, leading to more than 20 oxidized base adducts. As a
consequence of oxidation, DNA may have strand breaks, DNA-DNA and DNA-protein
crosslinking, and base modification. Several biomarkers of DNA damage have been
quantified, including 8-hydroxy-2’-deoxyguanosine (8-OHdG), the most studied
biomarker in DNA oxidation. In 1993, Mecocci et al. reported an age-depended increase
of the levels of 8-OHdG in both nDNA and mtDNA in human brain. Subsequently, she
observed increased levels of 8-OHdG in brain tissue of AD compared to normal aged
subjects (Mecocci et al. 1994). In 1998, Gabbita et al. reported increased levels of
multiple oxidized DNA bases in nDNA in AD subjects.
We hypothesized that oxidative damage to DNA, especially mtDNA, may play an
important role in the pathogenesis of Alzheimer’s disease.
To carry out this study, brain specimens from eight late-stage AD (LAD) (four
females, four males) and eight age-matched control subjects (four females, four males)
were used for the analysis of oxidative damage to DNA. Four brain regions (frontal lobe,
parietal lobe, temporal lob, and cerebellum) were used. Among them, cerebellum was
used as a control region compared to the other three neocortical regions.

1.7.2 Increased oxidative damage in nuclear and mitochondrial DNA in Mild
Cognitive Impairment
Recent emphasis in adult dementing disorders is on early detection with the hope
of early treatment to slow disease progression. Mild Cognitive Impairment (MCI) is
generally considered to be the transitional zone between normal aging and early
dementing disorders. In general, most MCI subjects eventually convert to AD or other
dementias with ~15% of MCI subjects converting to AD per year.

Several gene

mutations associated with AD have been observed in subjects with MCI including
mutations in apolipoprotein E, presenilin 1, and the amyloid precursor protein. Several
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studies of MCI show elevated levels of tau, Aβ, and isoprostanes in ventricular CSF, and
more recently significant elevations of DNA damage in peripheral leukocytes of MCI and
AD (Migliore et al. 2005).
As we saw elevated DNA oxidation in AD brain in our previous study, this study
tried to address when the oxidation begins in AD progression. Although increased DNA
oxidation is observed in the AD brain, it is unclear when the oxidative damage begins. To
determine if DNA oxidation occurs in the brain of subjects with MCI, we quantified
multiple oxidized bases in nuclear and mitochondrial DNA isolated from frontal, parietal
and temporal lobes and cerebellum of short post-mortem interval autopsies of eight
patients with amnestic MCI and six age-matched control subjects.

1.7.3

Increased oxidative damage in nuclear DNA in APP/PS1 transgenic mice
The amyloid cascade hypothesis suggests that Aβ processing and aggregation

may contribute to the pathogenesis of sporadic AD.

APP is cleaved by β- and γ-

secretases to produce Aβ mainly containing Aβ40 and Aβ42. The possible reason why
Aβ is toxic is that it may lead to the production of free radicals that result in the oxidation
of proteins, lipids, and DNA. More than 50 mutations have been identified in PS1, much
more than those of in PS2. Studies show increased Aβ42 production in PS1 transgenic
mouse (Duff et al. 1996).
APP transgenic mice show senile plaques in neocortex and hippocampus by 12
month of age. In the mouse model coexpressing APP and PS1, the deposition of senile
plaques get accelerated at early ages (Holcomb et al. 1998; Wengenack et al. 2000).
The present study was carried out to measure levels of oxidized nDNA bases in
the brain of APP/PS1 transgenic mice using GC/MS-SIM and stable isotope labeled
internal standards, and to study the relation of Aβ deposition and DNA oxidation. The
bases quantified were 8-hydroxyadenine and 8-hydroxyguanine, the most studied
biomarkers of DNA damage.

1.7.4 Proteomic Studies of Mitochondria in Alzheimer’s Disease
Mitochondria are the major source of free radicals in cells and their DNA and
proteins may be more easily oxidized than in the nucleus. Our previous studies show
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increased nuclear and mitochondrial DNA damage in LAD and MCI brain. The DNA
damage may lead to the altered protein expression in cells. Numerous studies also
showed protein changes in cultured neuron cells and AD brain (Butterfield and Castegna
2003; Choi et al. 2004; Lovell et al. 2005). Protein oxidation may affect neuron function
through damaging enzymes that are critical to neuron metabolism.
Proteomics provides an ideal way to study the mitochondrial proteome in AD
brain. Two-dimensional gel electrophoresis has the ability to resolve complex mixtures
of thousands of proteins in one gel.
Based on our results and previous studies of AD, we hypothesized that DNA
damage may alter protein expression in AD brain, especially in mitochondria. In this
study, we used proteomics to characterize protein changes in mitochondria in the brain of
five LAD and four age-matched control subjects.

Copyright © Jianquan Wang 2006
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CHAPTER TWO
Materials and Methods

2.1 Reagents
N, O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) and anhydrous pyridine were
from Aldrich Chemical (Milwaukee, WI, USA). Molecular biology grade phenol,
chloroform, isoamyl alcohol, proteinase K, sucrose, acetonitrile and other standard
chemicals for preparation of buffers were obtained from Sigma (St. Louis, MO, USA).
Stable labeled oxidized base analogues were from Cambridge Isotope
Laboratories (Andover, MA, USA). These included 8-[8-13C, 7, 9-15N2] hydroxyguanine,
8-[8-13C, 6, 9-diamino-15N2] hydroxyadenine, 5-[2-13C, 1, 3-15N2] hydroxycytosine, 5[13C4,
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N2] hydroxyuracil, [formyl-13C, diamino-15N2] fapyadenine, and [formyl-13C,

diamino-15N2] fapyguanine.
The oct-1 antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA)
and the porin antibody was from Oncogene (San Diego, CA, USA).
The DNA Extractor WB and mtDNA Extractor CT kits were from Wako
Chemicals USA, Inc. (Richmond, VA, USA).
IPG strips, Coomassie Blue G-250, Sypro ruby and the 2D starter kit were
purchased from Bio-Rad Laboratories (Hercules, CA, USA).

Percoll for gradient

centrifugation was from Amersham Biosciences (Piscataway, NJ, USA). The density
marker beads were from Amersham Pharmacia Biotech AB (Uppsala, Sweden).

2.2 Methods

2.2.1

Brain specimen sampling
Due to the low yield of mtDNA from brain samples, large (15–20 g) specimens of

frontal, temporal and parietal lobe and cerebellum were removed at autopsy, immediately
placed in liquid nitrogen and stored at −80°C until used for analysis. Although the
specimens were primarily composed of cerebral cortex and cerebellar cortex, some gyral
and subcortical white matter or folial white matter was present.
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All LAD patients were followed longitudinally at the University of Kentucky
Alzheimer's Disease Center (UK-ADC) Clinic. All AD subjects met standard clinical
diagnostic criteria for probable AD (McKhann et al. 1984) and met accepted
neuropathologic criteria for the diagnosis of AD (Mirra et al. 1991, Gearing et al. 1995,
Anon 1997).
All MCI patients were followed longitudinally at the UK-ADC Clinic and were
initially normal on enrollment but developed MCI during follow-up. The clinical criteria
for amnestic MCI were those described by Petersen et al. (1999) and include: (i) memory
complaints; (ii) expected memory impairment for age and education; (iii) normal general
cognitive function; (iv) intact activities of daily living and (v) the subject does not meet
criteria for dementia. Objective memory test impairment was based on a score ≤ 1 SD
from the mean of controls on the CERAD Word List Learning Task (Morris et al. 1989)
and corroborated in many cases with the Free and Cued Selective Reminding Test.
Patients with MCI showed a significant increase in neuritic plaques in neocortical regions
and a significant increase in neurofibrillary tangles in entorhinal cortex, hippocampus and
amygdala (Markesbery et al. 2006).
All control subjects were followed longitudinally in the UK-ADC Clinic and had
neuropsychological testing annually which remained in the normal range. Exclusionary
criteria included strokes, hemorrhages, history of hypoxia or hypoxic changes, systemic
disorders affecting the CNS and psychiatric or other neurological disorders. The most
frequent causes of death were myocardial infarcts, pneumonia, pulmonary emboli, cancer
(none of the patients had cerebral metastases) and congestive heart failure.
All patients had extensive neuropathological evaluation of multiple neocortical,
ventromedial temporal lobe, basal ganglia, brainstem and cerebellum sections using the
modified Bielschowsky stain, hemotoxylin-eosin and 10D-5 and alpha synuclein
immunostains. Braak staging (Braak and Braak 1991) was determined using the Gallyas
stain on sections of entorhinal cortex, hippocampus and amygdala and the Bielschowsky
stain on neocortex.
None of the subjects demonstrated significant Lewy body pathology.
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2.2.2

Isolation of nuclear DNA
Brain specimens from eight LAD (four females and four males) and eight age-

matched control (four females and four males) subjects were used for the analysis of
oxidative damage to DNA in the LAD study.
To examine oxidative DNA damage in MCI, brain specimens from eight MCI
(four females and four males) and six age-matched control (two females and four males)
subjects were used for DNA isolation.
To examine the effects of amyloid deposition on DNA oxidation, brain specimens
from APP/PS1 mice and wild type were used for the analysis of oxidative damage to
DNA. Four groups of different ages (3m, 6m, 9m, 12m) were used with 8 to 10 mice in
each group.
A modified procedure of Mecocci et al. (1993) was used to isolate DNA. Briefly,
brain specimens were homogenized on ice using a motor-driven Teflon-coated dounce
homogenizer in MSB-Ca2+ buffer (0.21 M mannitol, 0.07 M sucrose, 0.05 M Tris-HCl,
3 mM CaCl2, pH 7.5). Disodium EDTA was added to the homogenate with final
concentration at 0.01 M, followed by centrifugation at 1,500 x g at 4°C for 20 min. The
pellet was resuspended in MSB-Ca2+ buffer and centrifuged again. The combined
supernatant was kept for isolation of mtDNA and the resulting nuclear pellet was
suspended in digestion buffer (0.5% sodium dodecyl sulfate, 0.05 M Tris-HCl, 0.1 M
Na2EDTA) and incubated with 400 µg/mL proteinase K in a 55°C water-bath overnight.
Then, 160 µL of 5 M NaCl per 10 mL solution was added, followed by extraction three
times with buffer-saturated phenol containing 5.5 mM 8-hydroxyquinoline and three
times with chloroform/isoamyl alcohol (24 : 1). 8-hydroxyquinoline was used to limit
artifactual DNA oxidation. For the resulting clear solution, 800 µL 5 M NaCl per 10 mL
and an equal volume of chilled absolute ethanol were added to precipitate DNA. After
centrifugation, the DNA pellet was washed three times with 60% ethanol and air-dried.
The pellet was dissolved in autoclaved water and a Genesys 10UV spectrometer
(Rochester, NY, USA) used to measure concentration and purity of DNA samples at 260
and 280 nm. The ratio of A260/A280 was used to verify DNA purity.
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Due to the large sample size, DNA isolated in theses studies is probably from a
mixture of glia and neurons and represents a global measure of DNA oxidation. The
DNA was stored at −80°C until used for GC/MS-SIM analyses.

2.2.3

Isolation of mitochondria
The combined supernatant from above was centrifuged at 20,000 x g for 20 min.

The pelleted crude mitochondrial fraction was washed with MSB-Ca2+ buffer once. This
raw pellet still contained contaminants, including cytosolic proteins.
To further purify the mitochondria, it was resuspended in 2 mL MSB-Ca2+, loaded
onto the percoll/MSB-Ca2+ buffer (1 : 1), and centrifuged at 50,000 x g for 1 h. Several
bands were observed after centrifugation and the light brown band (1.035 g/ml) was
separated. This fraction was primarily composed of intact mitochondria.
The pelleted mitochondria were resuspended and centrifuged a second time
through a percoll gradient leading to highly purified intact mitochondria.
mitochondria were centrifuged and washed three times with MSB-Ca

2+

The

buffer. The

resulting pellet was used for isolation of mtDNA or protein.
To verify the purity of mitochondria, representative samples were fixed with 2.5%
glutaraldehyde, post fixed in 1% osmium tetroxide, dehydrated through graded ascending
alcohols and propylene oxide, and embedded in Spurr's low viscosity embedding media.
Sections were cut and analyzed by electron microscopy (EM) by the UK Electron
Microscopy Facility.

2.2.4

Isolation of mitochondrial DNA
For DNA isolation, the mitochondrial pellet from above was lysed by addition of

2% sodium dodecyl sulfate solution and 400 µg/mL proteinase K for 4 hr in a 37°C water
bath. After addition of 160 µL 5 m NaCl per 10 mL, the solution was extracted three
times with buffer-saturated phenol (5.5 mm 8-hydroxyquinoline) and chloroform/isoamyl
alcohol (24 : 1) as described above. mtDNA was precipitated with 800 µL 3m sodium
acetate and two volumes of absolute ethanol at −20°C overnight. mtDNA was pelleted at
14,000 x g for 20 min, washed with 60% alcohol, dried, then resuspended in 200 µL
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autoclaved water. The concentration was calculated based on the absorbance at 260 nm
measured by UV-Vis spectrometry.

2.2.5

Western blot analysis
To verify the purity of nuclear and mitochondrial fractions, nuclear and

mitochondrial proteins from representative AD and control subjects were dissolved in
distilled water. Protein concentrations were determined using the Pierce BCA method.
Protein (50 µg) was separated on a 4–20% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis gradient gel and was transferred to nitrocellulose. The blot was blocked in
5% milk in 0.5% Tween-20/Tris-buffered saline (TTBS) overnight at 4°C. Primary
antibodies (rabbit anti-porin [1 : 1000] and rabbit anti-oct-1 [1 : 500]) were added and
blots were incubated for 3 hr at room temperature. The blots were washed three times for
10 min each with TTBS and incubated in horseradish peroxidase conjugated secondary
antibody for 1 h. The blots were rinsed three times with TTBS and the bands visualized
using enhanced chemiluminescence per manufacturer's instructions (Amersham
Pharmacia Biotech, Piscataway, NJ, USA).

2.2.6

Polymerase chain reaction amplification of mitochondrial DNA and neural
DNA
To further verify that mtDNA was not contaminated by nDNA, PCR was

performed with 500 ng mtDNA and nDNA using primers for APOE, a nuclear-coded
protein. PCR reaction mixtures of 50 µL contained 1 × PCR buffer, 250 µm dNTPs,
0.625 U Taq polymerase, 1.5 mm MgCl2, and 500 ng DNA. Primer sequence were as
described by Tsukamoto et al. (1993); and were 5'-GGCGCTCGCGGATGGCGCTGAG3'(sense primer) and 5'-GCACGGCTGTCCAAGGAGCTGCAGGC-3' (reverse primer)
(Integrated Device Technology, Santa Clara, CA, USA) PCR products were separated on
a 2% low-melt agarose gel containing ethidium bromide as previously described (Addya
et al. 1997).
PCR amplification showed no cross-contamination between nDNA and mtDNA
(Wang et al. 2005).
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2.2.7

Isolation of nuclear DNA and mitochondrial DNA using NaI method
To ensure that phenol extraction did not lead to artifactual DNA oxidation, nDNA

and mtDNA were isolated from four representative frontal lobe specimens using DNA
Extractor WB and mtDNA Extractor CT kits (Wako Chemicals USA, Inc.) following the
manufacturer's instructions. To isolate nDNA, tissue specimens were homogenized in the
lysis buffer provided in the DNA Extractor WB kit. The homogenate was centrifuged at
1,500 x g and 4°C for 15 min and the pellet resuspended in enzyme reaction solution.
Proteinase K was added to a final concentration of 10 µg/mL and the solution was
incubated in a 55°C water-bath overnight. RNase was added to the solution at a final
concentration of 20 µg/mL and incubated for an additional 10 min. The supernatant was
collected after centrifugation at 10,000 x g and 25°C for 2 min. nDNA was precipitated
by the addition of 0.6 mL NaI solution from the kit and an equal volume of 100%
isopropanol.
For mtDNA isolation tissue specimens were homogenized in ice-cold
homogenization buffer provided in the mtDNA Extractor CT kit. The homogenate was
centrifuged at 1,500 x g and 4°C for 15 min. The supernatant was collected and
centrifuged at 20,000 g at 4°C for 20 min and solutions I, II and III from the kit were
added to the pellet as in the manufacturer's instructions. mtDNA was precipitated by the
addition of 0.3 mL NaI and an equal volume of 100% isopropanol. DNA concentrations
were measured by the absorbance at 260 nm.

2.2.8

Sample preparation for gas chromatography/mass spectrometry
nDNA (200 µg) and mtDNA (20 µg) were used for analysis by GC/MS-SIM.

Individual bases were prepared by acid hydrolysis and derivatization with BSTFA. The
DNA samples were added to 5-mL conical glass tubes with a Teflon disc screw cap.
Isotope-labeled internal standards were added for quantification of oxidized bases. Two
hundred and fifty microliters of 90% formic acid was used to hydrolyze DNA at 145°C
for 30 min in evacuated tubes. Acid hydrolysis releases intact and modified bases by
cleaving the bonds between bases and sugar moieties. After hydrolysis, the samples were
lyophilized and derivatized with a mixture of BSTFA/pyridine (1 : 1) at room
temperature for 2 h in evacuated tubes.
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The derivatized products were lyophilized again and dissolved in 20 µL BSTFA
immediately before analysis and 2 µL injected into the GC/MS-SIM for analysis.

2.2.9

Gas chromatography/mass spectrometry analysis
A Hewlett-Packard model HP6890 gas chromatograph interfaced with an MS

detector was used. The injection port was maintained at 250°C. A 5%
phenylmethylsiloxane capillary column (30 m, 0.25 mm i.d., 0.25 µm film thickness; HP5MS) was used for separation. Ultra-high-purity helium was used as a carrier gas at an
inlet pressure of 11.8 psi using constant flow and a splitless mode. The glass liner in the
injection port was filled with silanized glass wool, which allowed homogeneous
vaporization of injected samples. The initial temperature was held 2 min after sample
injection with the following ramps: ramp 1: 100–178°C at 3°C/min; ramp 2: 178–181°C
at 0.3°C/min; ramp 3: 181–208°C at 3°C/min; ramp 4: 208–280 at 10°C/min. The final
temperature was maintained for 2 min. The run time was 56.2 min for each sample. The
temperature of the ion source inside mass spectrometer was ~180°C.

2.2.10 Amyloid plaque counts
APP/PS1 mice were sacrificed by halothane overexposure using procedures
consistent with the Panel on Euthanasia of American Veterinarian Association. The
brains were quickly removed and a single hemisphere without cerebellum was placed in
4% phosphate buffered paraformaldehyde.

The hemisphere was dissected after

paraformaldehyde fixation for 7 days and embedded in paraffin. 10 µm sections were cut
using a Shandon Finesse microtome and placed on Plus slides.

Sections were stained

using a monoclonal antibody against Aβ17-34 (Vector Laboratories, Burlingame, CA)
using standard protocols.

Briefly, sections were deparaffinized through xylene and

graded descending alcohols to water, incubated 30 min at room temperature in 3%
H2O2/methanol, washed in distilled/deionized water, followed by 3 min incubation at
room temperature in 90% formic acid. The sections were washed 5 min in running
distilled/deionized water, pretreated 10 min at room temperature with 2 mg/ml pepsin
(Biomedia, Foster City, CA), blocked in 15% normal goat serum in automation buffer 1
hr at room temperature after 3 times (2 min each) washes in automation buffer. Sections
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were incubated in a 1:100 dilution of anti-Aβ at 4 oC overnight and washed 3 times (5
min each) with automation buffer. The sections were incubated 1 hr at room temperature
in horse anti-mouse IgG (1:2000) in 1.5% horse serum/automation buffer. The sections
were washed 3 times (5 min each) in automation buffer, incubated 30 min in Vector
laboratories ABC reagent, washed 3 times (5 min each) in automation buffer, and color
developed using DAB. Sections were counterstained using hematoxylin/ecosin,
dehydrated, cleared in xylene and coverslipped.

This work was done by Dr.

Markesbery’s neuropathology laboratory.
Aβ deposits were counted semi-quantitatively by taking serial micrographs of the
entire hemisphere of each animal using a 20X objective on a Nikon Eclipse E60
Microscope. Each Aβ deposit was circled and counted on the printed micrograph with
naked eye. Deposits considered as an independent plaque must be discrete and not
connected to another. The number of Aβ deposits were normalized to the area of the
section measured using Bioquant software. This work was carried out by Dr. WR
Markesbery.

2.2.11 Two-dimensional electrophoresis
Five hundred milligram lyophilized mitochondrial protein was dissolved in 300 µl
rehydration buffer (8.0 M urea, 4% CHAPS, 100 mM DTT (dithiothreitol), 0.001%
bromophenol blue, 0.2% Bio-Lytes) and loaded onto the 17 cm IPG (pI 3-10) strips. The
strips were rehydrated for 12 hr at room temperature under mineral oil. A pause is
needed after rehydration for inserting paper wicks, adding mineral oil, transferring strips
from rehydration tray to focusing tray per manufacture. Then a self-defined program
(300 V for 5 hr, 1,000 V for 1hr, 2,500 V for 1 hr, and 5,000 V for 80,000 voltage:hour)
was run for total time of about 23 hr.
Before running the second dimension, the strips were equilibrated with
equilibration buffer I (6 M urea, 2% SDS, 0.375 M Tris-HCl, 20% glycerol, 130 mM
DTT) and equilibration buffer II (6 M urea, 2% SDS, 0.375 M Tris-HCl, 20% glycerol,
130 mM iodoacetamide) for 20 min each. After equilibration, the strips were washed in
running buffer and loaded onto 8-16% SDS-PAGE gel. Running conditions were 16
mA/gel for 30 min, then 24 mA/gel for about 5 hr.
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2.2.12 Gel staining and image analysis
The gels were stained with Sypro ruby per manufacture’s instruction. Briefly, the
gels were fixed with 30% methanol/10% acetic acid for one hr. 250 ml of Sypro ruby
solution was used to stain the gels overnight in a dark box. The gels were washed with
20% ethanol 3 times (15 min each wash). Gel images were taken using a ChemiDoc
XRS system and analyzed with PDQuest software from Bio-Rad.
Spots stained with Sypro ruby can only be visualized under UV light. In order to
see spots under white light, the gels were stained with 0.1% Colloidal Coomassie
Brilliant Blue G250. Briefly, gels were fixed in fixing solution (1.3% phosphoric acid,
20% methanol), and stained overnight with fresh staining solution (0.1% Coomassie Blue,
1.6% phosphoric acid, 8% ammonium sulfate, 20% methanol). Gels were transferred to
neutralization buffer for 1-3 min (0.1 M tris-base, pH 6.5), followed by washing with
25% methanol for less than 1 min. Gels were stored in 20% ammonium sulfate at 4 oC
until the spots were cut for trypsin digestion.

2.2.13 Trypsin digestion for MS analysis
After PDQuest analysis, spots of interest were cut out as close to the edge of
spots as possible using glass Pasteur pipette. The gel pieces from single spot were
washed with water 3 times. 100 mM NH4HCO3 was added followed by addition of an
equal volume of acetonitrile. The solution was vortexed for 15 min and centrifuged at
10,000 g for 5 min. The gel pieces were dehydrated with 100 µl acetonitrile until they
stuck together. All liquid was removed. If gel particles were still blue (stained with
Coomassie Brilliant Blue), this step was repeated until gel became white. The pellet was
dried and rehydrated in 1.5 µM modified trypsin for 60 min at 4°C. Excess trypsin was
aspirated and the gel digested in a 60°C water bath overnight. 5% formic acid was added
to stop the digestion reaction. The supernatant is ready for MS.

2.2.14 MALDI-TOF analysis and database searching
A Bruker Autoflex MALDI-TOF (Matrix assisted laser desorption ionization –
time of flight) mass spectrometer (Bruker Daltonics, Billerica, MA, USA) at the
University of Kentucky Mass Spectrometry Facility was used to generate mass spectra.
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An AnchorChip target (Bruker Daltonics) was used to load trypsin digested samples. 1µl
of the supernatant was loaded onto an α-cyano-4-hydoxycinnamic acid (0.3 mg/ml in
ethanol: acetone, 2:1 ratio) spot. After the sample spot was air dried, 1 µl of 1% TFA
solution was used to wash the spot. The resulting spot was recrystallized with 1µl of a
solution of ethanol:acetone:0.1% TFA (6:3:1).
All spectra consist of at least 40 laser shots depending on the intensity of samples.
The MASCOT search engine was used to search proteins based on the peptide mass
fingerprints. The following parameters were used in database search: homo sapiens;
monoisotopic; oxidation (methionine); mass tolerance of 100 ppm; and up to one missed
trypsin cleavage.

2.3 Statistical Analysis
Statistical analyses of all the data were carried out using 2-way ANOVA and
ABSTAT software (Arvada, CO, USA).

p ≤ 0.05 was considered as a significant

difference. All results are expressed as mean ± SEM. Comparison of age and postmortem interval was by two-tailed Student's t-test. Braak staging scores were compared
using non-parametric testing and the Mann–Whitney U-test. Braak staging scores are
reported as the median.

Copyright © Jianquan Wang 2006
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CHAPTER THREE

Results

3.1 Increased oxidative damage in nuclear and mitochondrial DNA in late stage
Alzheimer’s disease
Mitochondrial density was measured using density marker beads. Results show
that mitochondria position at a density of 1.035 g/ml during centrifugation through a
percoll gradient (Figure 3-1). Electron microscopy of a representative mitochondrial
preparation isolated using our procedure showed a highly purified (~95%) mitochondrial
fraction (Figure 3-2).
We also carried out Western blot analysis of nuclear and mitochondrial protein
samples using Oct-1 and porin antibodies to verify the purity of nuclear and
mitochondrial fractions, respectively.

Western blot analysis (Figure 3-3) of

representative nuclear and mitochondrial fractions probed for Oct-1, an octamer-binding
protein specific to nuclei, and porin, a membrane-bound mitochondrial transport protein,
showed no cross contamination of proteins between the mitochondrial and nuclear
fractions. Figure 3-4 shows the results of PCR amplification of representative mtDNA
and nDNA samples for APOE, a nuclear-coded protein, and demonstrates that there was
no cross contamination of nDNA in mtDNA.
One representative DNA sample (50 µg) was run with six isotope-labeled internal
standards (1µg each). The chromatogram is shown in Figure 3-5. The bases of interest
were well separated, as indicated by their different retention times. 5-Hydroxyuracil was
eluted at a retention time of 18.4 min. The other oxidized bases were 5-hydroxycytosine
(21.7 min),

fapyadenine

(28.2 min),

8-hydroxyadenine

(32.2 min),

fapyguanine

(39.2 min), and 8-hydroxyguanine (44.5 min). We did not quantify modified thymine
because 5, 6-dihydroxythymine was below the minimum detection limit (Gabbita et al.
1998).
Three replicates were performed to determine the dynamic range of internal
standards. Results show that all internal standards had a large dynamic range.

5-
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hydroxyuracil showed a linear range from 6 pmol to 130 nmol (r = 0.9992) (Figure 3-6 b).
5-hydroxyuracil has three active hydrogen atoms from -NH and -OH groups, which are
replaced with -Si(CH3) from BSTFA during derivatization (Table 3-1). The resulting
molecular ion (M+) of the BSTFA derivative is 350 amu. With a loss of a CH3 group, the
daughter ion is observed at 335 amu (Figure 3-6 a). Similarly, three active hydrogen
atoms of 5-hydroxycytosine are replaced by –Si(CH3) during derivatization, resulting in
m/z values of 346 and 331 amu (Table 3-1, Figure 3-7 a). The linear range (r = 0.9995)
of 5-hydroxycytosine is from 2 pmol to 40 nmol (Figure 3-7 b). Three –Si(CH3) groups
replace three hydrogen atoms in fapyadenine, which results in m/z values of 372 amu for
the molecular ion and 357 amu for the daughter ion resulting from a loss of CH3 (Table
3-1, Figure 3-8 a). The linear dynamic range for fapyadenine is from 6 pmol to 120 nmol
(r = 0.9993) (Figure 3-8 b). 8-hydroxyadenine has three replaceable hydrogens during
derivatization by BSTFA, which results in m/z values of 370 amu (parent ion) and 355
amu (daughter ion) (Table 3-1, Figure 3-9 a). The standard curve of 8-hydroxyadenine
showed a wide dynamic range from 4 pmol to 90 nmol with an r of 0.9985 (Figure 3-9 b).
Four –Si(CH3) are added to fapyguanine in derivatization. The resulting mass of M+ is
460 amu. With a loss of CH3, the mass is 445 amu (Table 3-1, Figure 3-10 a). The linear
range of fapyguanine is from 7 pmol to 150 nmol (r = 0.9974) (Figure 3-10 b). Similar to
fapyguanine, 8-hydroxyganine has 4 replaceable hydrogen atoms, resulting in ions with
m/z values of 458 amu and 443 amu (Table 3-1, Figure 3-11 a). A linear response was
observed from 7 pmol to 130 nmol (Figure 3-11 b) for 8-hydroxyguanine.
To address the concern that artifactual oxidation of DNA occurred during phenol
extraction, we used DNA Extractor WB and mtDNA Extractor CT kits (Wako Chemicals
USA, Inc.) that use non-organic solutions and NaI precipitation. Table 3-2 shows that
levels of oxidized bases measured in DNA samples isolated using the two different
methods were similar, although levels of fapyguanine (p < 0.02) and fapyadenine
(p < 0.01) were significantly reduced in DNA isolated using the DNA Extractor WB kit
and levels of fapyadenine (p < 0.02) were significantly reduced with the mtDNA
Extractor CT kit. In contrast, levels of 5-hydroxycytosine (p < 0.02) were significantly
increased in DNA samples prepared using the mtDNA Extractor CT kit. Levels of 8hydroxyguanine and 8-hydroxyadenine showed no significant differences between the

41

two methods. Based on these data, DNA samples used for statistical comparisons were
isolated using phenol/chloroform extraction.
Eight AD and eight age-matched control DNA samples as previously described
were used in GC/MS-SIM analysis and six modified bases quantified using stable
isotope-labeled internal standards.

There were no significant differences in age or

postmortem interval (PMI) between LAD and age-matched control subjects (Table 3-3).
There was a significant difference in median Braak score between AD (VI) and agematched control subjects (I) (Table 3-3). The amount of each modified base is expressed
as mean ± SEM number of modified lesions per million DNA bases (Halliwell and
Dizdaroglu 1992) as shown in Table 3-4. Table 3-5 shows a comparison of levels of
oxidized bases in terms of lesions/106 DNA bases, lesions/unmodified DNA bases,
percentage of lesions, and nmol/mg DNA. Levels of modified bases in mtDNA were
statistically significantly (p < 0.01) higher than in nDNA for both LAD and control
subjects for each region. Comparison of the ratio of mitochondrial to nuclear DNA
oxidation showed no significant differences between LAD and control subjects due to
considerable subject to subject variability. In LAD samples, the damage was consistently
higher than controls. The absolute amount of 8-hydroxyadenine was the lowest among
the modified bases, whereas 8-hydroxyguanine was the highest.
Hydroxyl radical attack on the C8 of adenine leads to the production of 8hydroxyadenine. Mean levels of 8-hydroxyadenine were approximately twofold higher
in AD than in the controls, and mtDNA had approximately eightfold higher levels than
the nDNA. Significant differences were found in nDNA in the frontal lobe (p < 0.03) and
parietal lobe (p < 0.04), and nDNA (p < 0.001) and mtDNA (p < 0.04) of temporal lobe
in LAD. The absolute amount of 8-hydroxyadenine in LAD mtDNA of the temporal lobe
was the highest (Figure 3-12).
One electron reduction followed by ring opening of 8-hydroxyadenine leads to
formation of fapyadenine. Significant elevations of fapyadenine were present in mtDNA
of LAD parietal lobe (p < 0.05), nDNA (p < 0.001) and mtDNA (p < 0.05) of AD
temporal lobe, and nDNA of cerebellum (Figure 3-13).
5-Hydroxycytosine is formed by dehydration of cytosine glycol and 5hydroxyuracil by dehydration and deamination of cytosine glycol, the oxidation product
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of cytosine. Our data show that 5-hydroxycytosine was significantly elevated in AD
samples in nDNA (p < 0.01) and mtDNA (p < 0.01) of frontal lobe, mtDNA (p < 0.01)
of parietal lobe and nDNA (p < 0.001) and mtDNA (p < 0.05) of temporal lobe (Figure
3-14). 5-Hydroxyuracil levels were significantly elevated in mtDNA of parietal (p < 0.05)
and temporal (p < 0.04) lobes, and nDNA in temporal lobe of AD (p < 0.05) (Figure 315).
In our study, we observed levels of 8-hydroxyguanine considerably higher than
any of the other bases. Statistical comparison showed significant elevations of 8hydroxyguanine in nDNA in the frontal (p < 0.03) and parietal (p < 0.01) lobes of AD
subjects and in mtDNA of parietal (p < 0.05) and temporal (p < 0.05) lobes in AD
(Figure 3-16). Fapyguanine, which results from a one electron reduction and ring opening
product of 8-hydroxyguanine, was significantly elevated in mtDNA of cerebellum
(p < 0.04), and parietal (p < 0.05) lobe in AD (Figure 3-17).
Statistical results from two-way ANOVA showed that 8-hydoxyadenine (p < 0.02)
and 8-hydroxyguanine (p < 0.04) in AD nDNA were significantly increased in
neocortical regions compared to cerebellum (Table 3-4). In order to compare our results
easily to previous studies, a units conversion table is provided (Table 3-5).
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Table 3-1. m/z values of BSTFA derivatives of internal standards
Internal Standards
5-hydroxyuracil
5-hydroxycytosine
fapyadenine
8-hydroxyadenine
fapyguanine
8-hydroxyguanine

Molecular
weight
134
130
156
154
172
170

Addition of –
Si(CH3) groups
3
3
3
3
4
4

m/z of M+
350
346
372
370
460
458

m/z for
M+ – CH3
335
331
357
355
445
443
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Table 3-2. Comparison of two different DNA extraction methods
Level of modified bases (Lesions/106 DNA Bases, mean ± SEM)
Nuclear DNA
Mitochondrial DNA
PhenolWB kit (NaI)
PhenolCT kit(NaI)
Chloroform
Chloroform
Frontal lobe
8-OH-guanine
Fapyguanine
5-OH-cytosine
8-OH-adenine
Fapyadenine

50.4 ± 7.8
20.5 ± 2.3
8.2 ± 1.0
12.2 ± 2.3
12.9 ± 1.3

61.9 ± 21.6
12.1 ± 1.0*
26.2 ± 9.5
19.0 ± 7.0
4.6 ± 0.5*

262.7 ± 64.9
187.2 ± 75.1
78.0 ± 15.9
42.5 ± 12.5
72.6 ± 16.7

223.7 ± 53.4
154.5 ± 48.6
158.2 ± 21.9*
22.0 ± 10.1
7.3 ± 1.9*

* p < 0.05 phenol-chloroform vs. NaI precipitation
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Table 3-3. Demographic data for control and LAD subjects

Control
LAD

Number and
sex
N=8 (4F, 4M)
N=8 (4F, 4M)

Age (yr)
(mean ± SEM)
84.3 ± 3.4
85.1 ± 1.6

PMI (hr)
(mean ± SEM)
2.9 ± 0.2
3.3 ± 0.2

Braak Score
(median)
I
VI*

* p < 0.05 control vs. LAD
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Table 3-4. Levels of markers of DNA oxidation in nuclear and mitochondrial DNA
from late stage Alzheimer’s disease and age-matched control subjects.
Level of modified bases (Lesions/106 DNA Bases, mean ± SEM)
Nuclear DNA
Mitochondrial DNA
control
LAD
control
LAD
Cerebellum
8-OH-adenine
Fapyadenine
5-OH-cytosine
5-OH-uracil
8-OH-guanine
Fapyguanine

13.0 ± 2.2
7.2 ± 1.4
9.9 ± 1.1
6.9 ± 0.8
36.3 ± 4.9
14.8 ± 2.1

18.0 ± 2.1
13.2 ± 1.9*
14.9 ± 1.9
9.6 ± 2.1
49.4 ± 8.7
21.5 ± 3.2

96.1 ± 13.4
81.5 ± 13.1
90.0 ± 18.5
52.8 ± 12.3
205.0 ± 35.1
144.9 ± 23.2

136.9 ± 17.8
114.4 ± 14.4
226.6 ± 58.0
95.1 ± 21.9
439.6 ± 115.7
344.8 ± 70.5*

Frontal lobe
8-OH-adenine
Fapyadenine
5-OH-cytosine
5-OH-uracil
8-OH-guanine
Fapyguanine

11.8 ± 2.0
12.8 ± 1.2
9.4 ± 1.4
8.7 ± 1.4
49.4 ± 5.8
20.7 ± 2.1

28.3 ± 4.1*#
16.4 ± 3.2
16.6 ± 2.4*
10.9 ± 2.5
133.9 ± 25.8*#
22.3 ± 5.0

92.6 ± 8.9
73.1 ± 12.2
93.7 ± 19.8
39.4 ± 4.8
407.9 ± 70.7
238.7 ± 59.7

124.9 ± 16.9
101.7 ± 23.2
223.9 ± 22.4*
70.8 ± 21.5
568.5 ± 140.2
532.2 ± 131.4

Parietal lobe
8-OH-adenine
Fapyadenine
5-OH-cytosine
5-OH-uracil
8-OH-guanine
Fapyguanine

12.5 ± 1.6
12.7 ± 1.8
10.5 ± 1.3
9.8 ± 1.2
46.6 ± 4.9
17.0 ± 1.5

23.3 ± 3.9*#
15.7 ± 1.9
15.2 ± 1.8
13.9 ± 2.3
84.4 ± 10.4*#
38.7 ± 11.4

86.8 ± 10.4
71.7 ± 10.0
95.4 ± 12.6
27.3 ± 4.0
271.6 ± 34.1
178.5 ± 33.7

119.3 ± 15.4
108.1 ± 9.2*
217.7 ± 31.0*
68.4 ± 14.3*
646.9 ± 175.3*
370.8 ± 84.8*

Temporal lobe
8-OH-adenine
Fapyadenine
5-OH-cytosine
5-OH-uracil
8-OHguanine
Fapyguanine

12.7 ± 1.5
10.2 ± 1.3
7.6 ± 0.6
6.5 ± 0.6
72.8 ± 17.1
23.3 ± 3.6

35.7 ± 4.9 *#
18.1 ± 1.1*
15.5 ± 1.2*
11.3 ± 2.0*
142.5 ± 31.5#
41.6 ± 8.5

77.8 ± 10.4
79.4 ± 15.9
102.3 ± 22.4
30.5 ± 4.4
350.1 ± 81.8
178.4 ± 49.2

210.8 ± 48.6*
126.0 ± 13.6*
315.5 ± 95.1*
87.8 ± 19.8*
610.6 ± 158.9*
257.5 ± 31.6

* p < 0.05 significant elevations in LAD DNA compared to age matched control subjects
#
p < 0.05 significant elevations in DNA from frontal, parietal and temporal lobes
compared to cerebellum.
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Table 3-5. Comparison of levels of DNA damage in terms of lesions/106 total DNA
bases, ratio of lesion/unmodified DNA base, percentage of lesions, and nmol/mg of DNA
1
10
20
50
100
250
500
lesions/106 total
DNA bases
lesion:unmodified 1:250,000 1:25,000 1:12,500 1:5,000 1:2,500 1:1,000 1:500
DNA base
% of lesions
0.0004% 0.004% 0.008% 0.02% 0.04%
0.1% 0.2%
nmol lesions/mg
0.003
0.031
0.063
0.159
0.300
0.796 1.592
of DNA
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Figure 3-1. Mitochondrial density was measured using density marker beads.
Mitochondria were positioned at a density of 1.035 g/ml during centrifugation through a
Percoll gradient.
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Figure 3-2. Electron micrograph of a representative mitochondrial preparation after
centrifugation through Percoll gradients. Final magnitude is 32,500 X.
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Figure 3-3. Western blot analysis of protein from nuclei and mitochondria using
antibodies against Oct-1(a nuclear protein) and porin (a mitochondrial protein). The blots
show there was no cross contamination between nuclear and mitochondrial preparations.
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Figure 3-4. Two percent low-melt agarose gel of PCR amplified nDNA and mtDNA for
APOE, a nuclear encoded protein. It showed that there was no cross contamination
between nDNA and mtDNA.
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Figure 3-5. A representative gas chromatogram of a DNA sample with stable isotope labeled internal standards.
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Figure 3-6. (a) A representative mass spectrum of isotope-labeled 5-hydroxyuracil
(retention time 18.2 min). Figure (b) shows a standard curve of isotope-labeled 5hydroxyuracil, which has a good dynamic range from 6 pmol to 130 nmol.
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Figure 3-7. (a) A representative mass spectrum of isotope-labeled 5-hydroxycytosine
(retention time 21.7 min). Figure (b) shows a standard curve of isotope-labeled 5hydroxycytosine, which has a wide dynamic range from 2 pmol to 40 nmol.
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Figure 3-8. (a) A representative mass spectrum of isotope-labeled fapyadenine (retention
time 28.2 min). Figure (b) shows standard curve of isotope-labeled fapyadenine, which
has a wide dynamic range from 6 pmol to 120 nmol.
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Figure 3-9. (a) A representative mass spectrum of isotope-labeled 8-hydroxyadenine
(retention time 32.2 min). Figure (b) shows a standard curve of isotope-labeled 8hydroxyadenine, which has a wide dynamic range from 4 pmol to 90 nmol.
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Figure 3-10. (a) A representative mass spectrum of isotope-labeled fapyguanine
(retention time at 39.2 min). Figure (b) shows a standard curve of isotope-labeled
fapyguanine, which has a dynamic range from 7 pmol to 150 nmol.
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Figure 3-11. (a) A representative mass spectrum of isotope-labeled 8-hydroxyguanine
(retention time 44.5 min). Figure (b) shows a standard curve of isotope-labeled 8hydroxyguanine, which has a dynamic range from 7 pmol to 130 nmol.
59

8-hydroxyadenine mean ? SEM (Lesions/106 DNA Bases)

*
250

* p < 0.05 control vs. AD

200

150

100

50

*

*

*

0
CERBLM

FRONTAL

PARIETAL

TEMPORAL

Control nDNA
LAD nDNA
Control mtDNA
LAD mtDNA

Figure 3-12. Mean regional differences in levels of 8-hydroxyadenine. Significant
elevations were observed in nDNA of frontal (p < 0.03) and parietal (p < 0.04) lobes, and
nDNA (p < 0.01) and mtDNA (p < 0.04) of temporal lobe. Results are expressed as
mean ± SEM altered bases/106 bases. * p < 0.05
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Figure 3-13. Mean regional differences in levels of fapyadenine. Significant elevations
were observed in nDNA of cerebellum (p < 0.02), mtDNA of parietal lobe (p < 0.05), and
nDNA (p < 0.001) and mtDNA (p < 0.05) of temporal lobe. Results are expressed as
mean ± SEM altered bases/106 bases. * p < 0.05
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Figure 3-14. Mean regional differences in levels of 5-hydroxycytosine. 5hydroxycytosine was significantly elevated in AD samples in nDNA (p < 0.01) and
mtDNA (p < 0.01) of frontal lobe, mtDNA (p < 0.01) of parietal lobe and nDNA (p <
0.001) and mtDNA (p < 0.05) of temporal lobe. Results are expressed as mean ± SEM
altered bases/106 bases. * p < 0.05
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Figure 3-15. Mean regional differences in the levels of 5-hydroxyuracil. 5-hydroxyuracil
was significantly elevated in mtDNA from parietal (p < 0.05) and temporal (p < 0.04)
lobe of AD subjects. Results are expressed as mean ± SEM altered bases/106 bases. * p <
0.05
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Figure 3-16. Mean regional differences in the levels of 8-hydroxyguanine. There were
significant elevations of 8-hydroxyguanine in nDNA of frontal (p < 0.03) and parietal (p
< 0.01) lobes and in mtDNA of parietal (p < 0.05) and temporal (p < 0.05) lobes of AD
subjects. Results are expressed as mean ± SEM altered bases/106 bases. * p < 0.05
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Figure 3-17. Mean regional differences in the levels of fapyguanine. Fapyguanine was
significantly increased in mtDNA of cerebellum (p < 0.04) and parietal (p < 0.05) lobe of
AD brain. Results are expressed as mean ± SEM altered bases/106 bases. * p < 0.05
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3.2 Increased oxidative damage in nuclear and mitochondrial DNA in Mild
Cognitive Impairment
Subject demographic data are shown in Table 3-6. There were no significant
differences for age or PMI, although there was a significant difference in median Braak
staging scores between control (I) and MCI (III) (p < 0.001) subjects.
Table 3-7 shows levels of all five base adducts expressed as the mean ± SEM
number of modified bases per million DNA bases. Two-way

ANOVA

showed that 8-

hydroxyguanine (p < 0.04), fapyadenine (p < 0.001) and 5-hydroxycytosine (p < 0.004)
in mtDNA were significantly increased in neocortical regions compared with cerebellum
in MCI (Table 3-7) but not in control subjects. A similar comparison of data for nDNA
showed no significant differences between cerebellum and neocortical regions for either
MCI or control subjects.
Hydroxyl radicals can adduct to C8 and C5 of guanine.

The C8 attack is

predominant and leads to formation of 8-hydroxyguanine. Significant elevations of 8hydroxyguanine were observed in nDNA from frontal and parietal (p < 0.04) lobes and
mtDNA of temporal lobe (p < 0.05) in MCI (Figure 3-18). Comparison of 8hydroxyguanine in MCI mtDNA showed no significant differences between MCI and
LAD subjects from our previous study (Wang et al. 2005) suggesting that oxidative DNA
damage occurs early in the progression of AD. Fapyguanine is produced by ring opening
of 8-hydroxyguanine followed by one electron reduction and was not significantly altered
in mtDNA or nDNA of any MCI brain region studied compared with control subjects
(Figure 3-17).
5-Hydroxycytosine, produced by free radical attack on C5 of cytosine followed by
dehydration of cytosine glycol, was significantly elevated in nDNA of frontal (p < 0.01),
parietal (p < 0.05) and temporal (p < 0.01) lobes and mtDNA of frontal lobe (p < 0.003)
in MCI (Figure 3-18). Comparison of levels of 5-hydroxycytosine in MCI with those in
late-stage AD (Wang et al. 2005) showed no significant differences suggesting that
oxidative damage to cytosine is an early event in the pathogenesis of AD.
As shown in Figure 3-19, levels of 8-hydroxyadenine were significantly increased in
MCI nDNA from frontal (p < 0.05), parietal (p < 0.02) and temporal (p < 0.007) lobes
consistent with our observations in late-stage AD (Wang et al. 2005). However, no
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significant differences in levels of 8-hydroxyadenine were observed in mtDNA between
MCI and control subjects. These data are in contrast to our previous study of late-stage
AD subjects that showed a significant elevation of 8-hydroxyadenine in mtDNA from
late-stage AD temporal lobe (Wang et al. 2005).

Figure 3-20 shows that levels of

fapyadenine were significantly elevated in both nDNA and mtDNA of frontal, parietal
and temporal lobes in MCI compared with age-matched control subjects. Levels of 8hydroxyadenine and fapyadenine in MCI were not significantly different from those
observed in our previous study of late-stage AD brain (Wang et al. 2005).
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Table 3-6. Demographic data for control and MCI subjects
Number and
sex
Control
MCI

N=6 (3F, 3M)
N=8 (6F, 2M)

Age (yr)
(mean ±
SEM)
81.0 ± 3.8
89.5 ± 4.8

PMI (hr)
(mean ±
SEM)
3.0 ± 0.4
4.0 ± 0.9

Braak
Score
(median)
I
III*

ApoE
genotype
E3/E3, N=6
E3/E3, N=6
E4/E4, N=2

* p < 0.05 control vs. MCI
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Table 3-7. Levels of DNA oxidation in nuclear and mitochondrial DNA in MCI and
age-matched control subjects
Level of modified bases (Lesions/106 DNA Bases, mean ± SEM)
Nuclear DNA
Mitochondrial DNA
control
MCI
control
MCI
Cerebellum
8-OH-guanine
Fapyguanine
5-OH-cytosine
8-OH-adenine
Fapyadenine

40.8 ± 6.9
6.5 ± 1.8
11.6 ± 1.2
12.9 ± 2.5
14.9 ± 2.6

95.2 ± 38.0
21.0 ± 9.6
20.7 ± 4.9
16.7 ± 5.9
20.8 ± 4.5

227.1 ± 35.5
131.2 ± 33.2
92.5 ± 23.2
50.8 ± 11.2
75.3 ± 17.1

307.2 ± 75.9
133.4 ± 9.6
124.2 ± 4.8
47.2 ± 4.9
72.2 ± 5.3

Frontal lobe
8-OH-guanine
Fapyguanine
5-OH-cytosine
8-OH-adenine
Fapyadenine

50.4 ± 7.8
20.5 ± 2.3
8.2 ± 1.0
12.2 ± 2.3
12.9 ± 1.3

143.8 ± 53.4*
19.9 ± 1.2
32.8 ± 6.6*
24.1 ± 4.9*
27.8 ± 5.2*

262.7 ± 64.9
187.2 ± 75.1
78.0 ± 15.9
42.5 ± 12.5
72.6 ± 16.7

329.4 ± 128.6#
237.3 ± 48.5
257.8 ± 37.4*#
53.1 ± 15.4
158.1 ± 9.6*#

Parietal lobe
8-OH-guanine
Fapyguanine
5-OH-cytosine
8-OH-adenine
Fapyadenine

46.4 ± 6.0
16.6 ± 1.5
10.0 ± 1.3
12.5 ± 1.6
12.5 ± 1.7

149.1 ± 41.4*
18.3 ± 0.9
35.3 ± 9.9*
26.2 ± 4.3*
40.7 ± 9.1*

293.0 ± 45.0
158.8 ± 41.3
88.1 ± 13.4
64.4 ± 18.3
77 ± 12.6

343.0 ± 63.9#
158.5 ± 20.1
92.7 ± 23.2#
74.6 ± 9.2
158.8 ± 10.4*#

Temporal lobe
8-OH-guanine
Fapyguanine
5-OH-cytosine
8-OH-adenine
Fapyadenine

69.0 ± 18.4
22.0 ± 4.5
8.1 ± 0.9
14.2 ± 1.6
10.3 ± 1.6

135.1 ± 22.7
21.4 ± 1.4
24.5 ± 4.6*
25.8 ± 2.9*
29.1 ± 5.5*

271.5 ± 46.9
127.4 ± 50.4
107.0 ± 29.6
48.8 ± 10.0
69.8 ± 19.7

460.3 ± 83.5*#
159.6 ± 16.9
187.4 ± 50.5#
66.5 ± 9.9
177.1 ± 10.8*#

* p < 0.05 significant elevation in MCI DNA compared to age matched control subjects
#
p < 0.05 significant elevations in DNA from frontal, parietal and temporal lobes
compared to cerebellum.
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Figure 3-18. Mean regional levels of 8-hydroxyguanine. There was a statistically
significant elevation of 8-hydroxyguanine in MCI in nDNA of frontal (P < 0.05) and
parietal (P < 0.04) lobes, and mtDNA of temporal lobe (P < 0.05). Results are expressed
as mean ± SEM altered bases/106 bases. * P < 0.05
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Figure 3-19. Mean regional differences in levels of fapyguanine. Results are expressed
as mean ± SEM altered bases/106 bases. * P < 0.05
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Figure 3-20. Mean regional differences in levels of 5-hydroxycytosine. There were
significant elevations in MCI in nDNA of frontal (P < 0.01), parietal (P < 0.05) and
temporal (P < 0.01) lobes, and mtDNA of frontal lobe (P < 0.003) compared to agematched control subjects. Results are expressed as mean ± SEM altered bases/106 bases.
* P < 0.05
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Figure 3-21. Mean regional levels of 8-hydroxyadenine. There were significant
elevations in nDNA of frontal (P < 0.05), parietal (P < 0.02), and temporal (P < 0.007)
lobes. Results are expressed as mean ± SEM altered bases/106 bases. * P < 0.05
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Figure 3-22. Mean regional differences in levels of fapyadenine. There were significant
elevations in MCI in nDNA of frontal (P < 0.02), parietal (P < 0.02) and temporal (P <
0.02) lobes, and mtDNA of frontal (P < 0.0007), parietal (P < 0.0002) and temporal (P <
0.0002) lobes. Results are expressed as mean ± SEM altered bases/106 bases. * P < 0.05
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3.3 Increased oxidative damage in nuclear DNA in APP/PS1 transgenic mice

To evaluate the effects of Aβ deposition on DNA oxidation, one third of cortex
from APP/PS1 (ages 3, 6, 9, 12 months) and wild type mice were used for the analysis of
oxidative damage to nDNA. Each group consisted of 8 to 10 mice. Damage to nDNA
was quantified in this study because the brain tissue was too small to get enough mtDNA
for GC/MS-SIM analysis. Phenol-chloroform extraction was used in nDNA extraction as
previously described.
Figure 3-23 shows amounts of oxidized DNA base adducts expressed as the
mean ± SEM number of modified bases per million DNA bases.

Levels of 8-

hydroxyguanine were consistently higher than the levels of 8-hydroxyadenine both in
wild type and APP / PS1 mice (p < 0.001).
C8 attack on guanine by hydroxyl radicals leads to formation of 8hydroxyguanine, the most studied adduct in DNA oxidation. Significant elevations of 8hydroxyguanine in 12-month old APP / PS1 mice (p < 0.05) compared to 12-month WT
were observed (Figure 3-23).

Hydroxyl radical attack on C8 of adenine leads to

production of 8-hydroxyadenine. No significant change was observed between wild type
and APP / PS1 mice at any age (Figure 3-23). Using ANOVA there was no significant
age-dependent changes observed.
Aβ plaque counts were performed by Dr. WR Markesbery’s laboratory (Table 38). A statistically significant positive correlation between plaque counts and the levels of
8-hydroxyguanine in APP / PS1 mice was observed (r = 0.90).
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Table 3-8. Aβ plaque burden of WT and APP/PS1 mice

WT
APP/PS1

3 month
0
0

6 month
0
0.81 ± 0.12*

9 month
0
1.37 ± 0.13*

12 month
0
1.88 ± 0.13*

* p < 0.05 WT vs. APP/PS1
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Figure 3-23. Mean levels of 8-hydroxyadenine and 8-hydroxyguanine in APP/PS1 and
WT mice. There was significant elevations in the level of 8-hydroxyguanine in APP/PS1
in nDNA of 12-month mice compared to wild type. Results are expressed as mean ±
SEM altered bases/106 bases. No significant difference was observed in levels of 8hydroxyadenine. * P < 0.05
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Figure 3-24.

A positive correlation between plaque counts and the levels of 8-

hydroxyguanine in APP/PS1 mice (r = 0.90)
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3.4 Proteomic studies of mitochondria in Alzheimer’s disease

Based on our previous DNA studies, protein expression in mitochondria was
expected to be altered in LAD. Proteomics is an efficient way to study these changes. In
this study, mitochondrial proteins from temporal pole specimens of 5 LAD (3 female, 2
male) and 4 (2 female, 2 male) age-matched control subjects were analyzed. Subject
demographic data are shown in Table 3-9. There were no significant differences in age
or PMI between LAD and control subjects using Student’s t-test. There was a significant
difference in median Braak staging scores between control (I) and LAD (VI) (p < 0.001)
subjects.
Mitochondrial protein was isolated using Percoll gradient centrifugation as
previously described. 500 µg protein was used for 2D gel electrophoresis. After Sypro
ruby staining, ~650 protein spots on each gel were detected by PDQuest software. A
representative gel is shown in figure 3-24. An IPG strip (pH 3-10 nonlinear) was used in
the first dimension and an 8-16% SDS gel was used to separate proteins in the second
dimension. Proteins identified were labeled on gel (Figure 3-24). Molecular weights of
mitochondrial proteins detected ranged from 10 to 80 kDa.
A MALDI mass spectrum for a representative protein spot is shown in figure 3-25.
Every peak in the spectrum represents a specific peptide which was characterized by its
m/z value. The mass of peptides in the mass spectrum ranged from 800 to 2,000 Da. MS
data were submitted to the Mascot database in the form of peptide mass fingerprint
(PMF). By comparing these experimental data to the existing calculated peptide mass,
the matched proteins were identified. Only proteins with the lowest probability were
assigned as the best match. In this study, a Mowse score ≥ 52 was considered a
significant match (p < 0.05). Figure 3-26 shows the probability based Mowse score of
ATP synthase beta chain protein. 176 spots were identified and listed alphabetically in
Table 3-10 out of ~250 intense spots excised manually and analyzed. 116 out of 176
spots were unique proteins (Table 3-10).
Of the spots identified as differentially expressed, 116 spots representing 67
proteins were mitochondrial proteins.

23 spots were cytoplasmic proteins which

represent 18 different proteins. 10 spots represented 7 endoplasmic reticulum proteins. 6
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spots were 6 nuclear proteins. 2 spots were 1 lysosomal protein. Results were expressed
based on protein’s subcellular locations (Figure 3-27).
The 66 mitochondrial proteins were classified into 11 categories based on
function (Figure 3-28).

70% of these proteins were involved in oxidative

phosphorylation (OXPHOS), redox, tricarboxylic acid (TCA) cycle, carbohydrate
metabolism, nucleotide metabolism, lipid metabolism and glycolysis. The remaining
30% were involved in DNA/RNA/protein synthesis, signaling proteins, targeting proteins,
and transporter proteins.
Student’s t test was used to compare alterations in protein expression. 10 of 116
proteins were found to be significantly different in LAD brain (p < 0.05) (Table 3-11).
Two cytoplasmic proteins were significantly increased in LAD. Five mitochondrial
proteins were significantly decreased in LAD, in which 2 mitochondria-encoded proteins
from mitochondrial inner membrane were highlighted. One nuclear, one ER, and one
cytoplasmic protein were significantly decreased in LAD brain.
Western blots were used to verify proteomics results for representative proteins.
Because no commercial antibodies were available for the significantly altered proteins,
we used rabbit anti-VDAC and rabbit anti-CNPase for Western analysis. No significant
difference was observed in Western blots for either protein, which were consistent with
our findings using 2D gel analysis (Figure 3-29).
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Table 3-9. Demographic data of LAD and control subjects
Number and
sex
Control N=4 (2F, 2M)
LAD
N=5 (3F, 2M)

Age (mean ±
SEM)
82.8 ± 3.9
88.2 ± 3.6

PMI (mean ±
SEM)
2.9 ± 0.5
3.8 ± 0.9

Braak Score
(median)
I
VI*

* p < 0.05 control vs. LAD
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Table 3-10. Protein spots identified with MALDI-TOF MS in two-dimensional gels
Spot
#

Protein name

Accession
Number

Mowse
score

4403

26S protease
regulatory subunit
8
39S ribosomal
protein L12,
mitochondrial
[Precursor]
3-hydroxyacylCoA
dehydrogenase
type II
Aconitate
hydratase,
mitochondrial
[Precursor]
Actin,
cytoplasmic 1
Adenylate kinase
isoenzyme 4,
mitochondrial
Alanyl-tRNA
synthetase
Aldehyde
dehydrogenase,
mitochondrial
[Precursor]
Alpha crystallin B
chain
Alpha enolase
Annexin A5
ATP synthase
alpha chain,
mitochondrial
[Precursor]

P47210

6102

7303

7901
7902
7903
1505
2502
9304
2806
3808
4701
4702
5205
6601
1402
0805
5503
8702
8705
8706
9503
9504
1401
1701

M.W
(Da)

PI

Subcellular
Location

52

Sequence
Coverage (%)
20

45,597

7.11

Cytoplasmic
and nuclear

P52815

55

19

21,335

9.04

Mitochondrial

Q99714

95

43

26,906

7.66

Mitochondrial

Q99798

55
56
65

10
10
11

85372

7.36

Mitochondrial

P02570

32
33
33

41,710

5.29

Cytoplasmic

P27144

123
129
76

25,252

8.47

Mitochondrial
matrix

P49588

52

5

5.31

Cytoplasmic

P05091

106
80
125

23
17
18

10673
4
56,346

6.63

Mitochondrial
matrix

P02511

76

26

20,146

6.76

Unknown

P06733
P08758
P25705

62
212
54
103
196
215
123
62
153
124
191

18
47
20
22
36
39
26
10
27
33
40

47,002
35,783
59,714

6.99
4.94
9.16

Cytoplasmic
Unknown
mitochondrial
inner
membrane

82

0206
9008
9205

8102
8103
0804
2402
2404
2605
7501
7502
8501
7301
3603
4004
6803
6804

5804
6801
6802

ATP synthase D
chain,
mitochondrial
ATP synthase E
chain,
mitochondrial
ATP synthase O
subunit,
mitochondrial
[Precursor]
ATPase inhibitor,
mitochondrial
[Precursor]
Calreticulin
[Precursor]
Cathepsin D
[Precursor]
Creatine kinase
B-type
Creatine kinase,
ubiquitous
mitochondrial
[Precursor]
CTD small
phosphatase-like
protein
cyclic-nucleotide
3'phosphodiesterase
Cytochrome c
oxidase
polypeptide VIb
Delta-1-pyrroline5-carboxylate
dehydrogenase,
mitochondrial
[Precursor]
Dihydrolipoyl
dehydrogenase,
mitochondrial
[Precursor]

Table 3-10. (continued)
O75947
67
43

18,348

5.22

Mitochondrial

P56385

76

76

7,797

9.34

Mitochondrial

P48047

121

52

23,263

9.97

Mitochondrial
matrix

Q9UII2

60
58

33
35

12,241

9.34

Mitochondrial

P27797

89

19

48,112

4.29

cytoplasmic

P07339

64
70
107

16
18
27

44,524

6.10

Lysosomal

42,617

5.34

Cytoplasmic

P12532

106
106
53

26
26
16

47,007

8.60

O15194

57

13

37,851

8.95

Mitochondrial
inner
membrane;
outer side
Nuclear

P09543

58

12

47,579

8.90

Mitochondrial

P14854

55

47

10,055

6.78

Mitochondrial

P30038

73
181

7
33

61,713

8.25

Mitochondrial
matrix

P09622

103
54
64

24
11
15

54,116

7.59

Mitochondrial
matrix

P12277

83

4710

3806
3506

4402

7401

8304
5602
5604
5605
4303

0802
0403
7105
3203

Table 3-10. (continued)
P36957
131
25

48,609

9.01

Mitochondrial

76

16

62,255

5.95

Cytoplasmic

54

18

69,828

9.46

Mitochondrial

56

10

36,922

9.34

Endoplasmic
reticulum

60

17

35,058

8.62

Mitochondrial
matrix

86

32

27,826

8.24

Mitochondrial
matrix

80
156
215
84

20
35
41
33

49,510

7.26

Mitochondrial

28,975

6.77

Endoplasmic
reticulum

130

22

92,411

4.76

ER

53

12

54,813

7.98

cytoplasmic

53

22

23,484

8.89

Secreted

53

20

26,509

10.4
4

Unknown

Dihydrolipoyllysi
ne-residue
succinyltransferas
e component of 2oxoglutarate
dehydrogenase
complex,
mitochondrial
[Precursor]
Dihydropyrimidin Q16555
ase related
protein-2
DNA
Q969P6
topoisomerase I,
mitochondrial
[Precursor]
DolichylQ9Y673
phosphate betaglucosyltransferas
e
Electron transfer P13804
flavoprotein
alpha-subunit,
mitochondrial
[Precursor]
Electron transfer P38117
flavoprotein betasubunit
Elongation factor P49411
Tu, mitochondrial
[Precursor]
Endoplasmic
P30040
reticulum protein
ERp29
[Precursor]
Endoplasmin
P14625
[Precursor]
Fatty aldehyde
P51648
dehydrogenase
Fibroblast growth Q9NP95
factor-20
Fibroblast growth P55075
factor-8
[Precursor]
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8502 Fructosebisphosphate
aldolase
6501
Fructosebisphosphate
aldolase C
6602
Fumarate
6603
hydratase,
7601
mitochondrial
7602
[Precursor]
1101
Galectin-1
5702
Glutamate
5703 dehydrogenase 1,
5704
mitochondrial
7701
[Precursor]
6701
Glutamate
6703 dehydrogenase 2,
mitochondrial
[Precursor]
5805
Glycerol-35809
phosphate
dehydrogenase,
mitochondrial
[Precursor]
9305
GTP:AMP
phosphotransferas
e mitochondrial
4005
Guanine
nucleotidebinding protein
G(I)/G(S)/G(O)
gamma-5 subunit
1504
Guanine
3502
nucleotidebinding protein
G(I)/G(S)/G(T)
beta subunit 1
1403
Guanine
nucleotidebinding protein
G(I)/G(S)/G(T)
beta subunit 2
1501
Heat shock
cognate 71 kDa
protein

Table 3-10. (continued)
P04075
53
8

39,264

8.39

Mitochondrial

P09972

124

32

39,300

6.46

Mitochondrial

P07954

63
52
167
167
53
75
134
68
135
52
114

18
12
30
30
38
18
28
13
29
10
20

54,602

8.85

Mitochondrial
and
cytoplasmic

14,575
61,359

5.34
7.66

Unknown
Mitochondrial
matrix

61,395

8.63

Mitochondrial
matrix

P43304

90
33

16
11

80,764

6.98

Mitochondrial

Q9UIJ7

131

48

25,419

9.16

Mitochondrial
matrix

P63218

48

30

7,314

9.90

Mitochondrial

P62873

53
53

12
12

37,353

5.60

Mitochondrial

P62879

61

17

37,307

5.60

Mitochondrial

P11142

76

10

70,898

7.80

Cytoplasmic

P09382
P00367

P49448
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9004 heat shock protein
(10 kDa),
mitochondrial
1801 heat shock protein
2801
(60 kDa),
2802
mitochondrial
2803
[Precursor]
2808
7004
heat shock
protein1 (10
kDa),
mitochondrial
1901
Huntingtin
interacting
protein 1
4807
Hypothetical
protein
KIAA0555
0107
9007
3604
8604

5701

hypothetical
RNA-binding
protein
Hypoxiainducible gene
protein 2
Inositol 1,4,5trisphosphate
receptor type 1
Isocitrate
dehydrogenase
[NADP],
mitochondrial
[Precursor]
Lipoamide
acyltransferase
component of
branched-chain
alpha-keto acid
dehydrogenase
complex,
mitochondrial
[Precursor]

Table 3-10. (continued)
Q04984
95
59

10,794

8.91

Mitochondrial
matrix

P10809

16
34
18
22
26
39

61,016

5.70

Mitochondrial
matrix

P61604

79
199
82
129
199
87

10,794

8.91

Mitochondrial
matrix

O00291

53

7

11540
4

5.20

Cytoplasmic

Q96AA
8

58

7

94,875

5.88

Unknown

P42696

54

21

25,187

9.75

nuclear

Q9Y5L2

52

31

6,946

6.72

Unknown

Q14643

73

6

31394
5

7.20

Endoplasmic
reticulum

P48735

52

16

50,877

8.88

Mitochondrial

P11182

122

26

53,453

8.71

Mitochondrial
matrix

86

6805

7801
8801
8802

5504
5501

2506
7102

3102

MethylcrotonoylCoA carboxylase
beta chain,
mitochondrial
[Precursor]
Methylmalonatesemialdehyde
dehydrogenase
[acylating],
mitochondrial
[Precursor]
Mitochondrial
28S ribosomal
protein S22
Mitochondrial
import inner
membrane
translocase
subunit TIM9 A
Myosin Id
NADHubiquinone
oxidoreductase 13
kDa-A subunit,
mitochondrial
[Precursor]

NADHubiquinone
oxidoreductase 13
kDa-B subunit
1204
NADHubiquinone
oxidoreductase 23
kDa subunit,
mitochondrial
[Precursor]
4201
NADHubiquinone
oxidoreductase 24
kDa subunit,
mitochondrial
[Precursor]

Table 3-10. (continued)
Q9HCC
112
20
0

61,294

7.57

Mitochondrial
matrix

Q02252

93
57
109

15
10
21

57,803

8.72

Mitochondrial

P82650

159

34

41,254

7.70

Mitochondrial

Q9Y5J7

52

47

10,371

6.71

Mitochondrial
inner
membrane

O94832
O75380

55
53

12
34

78740
13,703

9.58
8.59

Unknown
inner
membrane

Q16718

68

40

13,327

5.70

Mitochondrial
inner
membrane

P80269

105

23

23,690

6.00

mitochondrial
inner
membrane

P19404

62

27

27,374

8.22

mitochondrial
inner
membrane

87

2302

NADHubiquinone
oxidoreductase 30
kDa subunit,
mitochondrial
[Precursor]

5603

NADHubiquinone
oxidoreductase 39
kDa subunit,
mitochondrial
[Precursor]
NADHubiquinone
oxidoreductase 51
kDa subunit,
mitochondrial
[Precursor]
NADHubiquinone
oxidoreductase 75
kDa subunit,
mitochondrial
[Precursor]
NADHubiquinone
oxidoreductase 9
kDa subunit,
mitochondrial
[Precursor]
NADHubiquinone
oxidoreductase
PDSW subunit
NipSnap1 protein

8601

2902

9006

9201

9303
3505
6103

Nucleoprotein
TPR
Origin
recognition
complex subunit
6

Table 3-10. (continued)
O75489
52
16

30,223

6.69

Mitochondrial
inner
membrane

Q16795

52

14

42,483

9.81

Mitochondrial
matrix

P49821

57

11

50,817

8.29

Matrix side of
the
mitochondrial
inner
membrane.

P28331

175

27

79,523

5.80

mitochondrial
inner
membrane

P56181

64

24

11,933

9.72

Mitochondrial
inner
membrane;
matrix side

O96000

67

26

20,632

8.77

Q9BPW
8
P12270

91

22

33,289

9.35

Mitochondrial
inner
membrane;
matrix side
Unknown

54

6

5.1

Q9Y5N
6

52

18

26544
1
28,089

8.91

nuclear pore
complex
Nuclear

88

8108
9103

3201
4401
7101
8201
3304

2403
3301
3303
0602
0803
3809
3901
4803
0501
9102
5501

3401

Peptidyl-prolyl
cis-trans
isomerase A
Peptidyl-prolyl
cis-trans
isomerase B
[Precursor]
Peroxiredoxin 2
Peroxiredoxin 6
Phosphatidyletha
nolamine-binding
protein
Potential
phospholipidtransporting
ATPase IIA
Prohibitin
Protein disulfideisomerase
[Precursor]
Protein disulfideisomerase A3
[Precursor]
Protein
NipSnap3A
Putative RNAbinding protein 3
Pyruvate
dehydrogenase
E1 component
alpha subunit,
somatic form,
mitochondrial
[Precursor]
Pyruvate
dehydrogenase
E1 component
beta subunit,
mitochondrial
[Precursor]

Table 3-10. (continued)
P05092
67
26

17,870

7.82

Cytoplasmic

P23284

103

39

22,728

9.33

Endoplasmic
reticulum

P32119
P30041
P30086

67
51
55
75

27
20
27
37

21,878
24,888
20,913

5.66
6.02
7.42

Cytoplasmic
Cytoplasmic
Cytoplasmic

O75110

56

7

11850
6

8.00

Integral
membrane
protein

P35232

152
53
59
65
87

45
12
15
15
21

29,786

5.57

Cytoplasmic

57,081

4.76

Endoplasmic
reticulum

115
77
93
53

25
17
20
19

56,747

5.98

Endoplasmic
reticulum

28,449

9.21

Unknown

64

26

17,160

8.86

Mitochondrial

P08559

133

26

43,268

8.35

Mitochondrial
matrix

P11177

53

25

3,1949

6.20

Mitochondrial
matrix

P07237
P30101
Q9UFN
0
P98179

89

4709

2508
3302
6301
1201
8106

1104
1202
5301
2804
3801
3803
9302

4804
4805
5801

6202

4502
5505

Pyruvate
dehydrogenase
protein X
component,
mitochondrial
[Precursor]
Ras-related
protein Rab-17
Ras-related
protein Rab-39A
Rho GDPdissociation
inhibitor 1
Single-stranded
DNA-binding
protein,
mitochondrial
[Precursor]
Sorcin
SSX5 protein
Stress-70 protein,
mitochondrial
[Precursor]
Succinate
dehydrogenase
[ubiquinone]
iron-sulfur
protein,
mitochondrial
[Precursor]
Succinyl-CoA:3ketoacidcoenzyme A
transferase 1,
mitochondrial
[Precursor]
Superoxide
dismutase [Mn],
mitochondrial
[Precursor]
Synaptotagmin-1

Table 3-10. (continued)
O00330
67
14

54,089

8.80

Mitochondrial
matrix

Q9H0T7

16
29
22

23,460

7.70

Mitochondrial

Q14964

53
57
52

24,854

6.90

Mitochondrial

P52565

83

29

23,195

5.02

Cytoplasmic

Q04837

65

45

17,870

9.59

Mitochondrial

P30626

97
117
53
53
229
252
62

37
31
20
12
32
38
27

21,662

5.32

Cytoplasmic

21,615
73,635

9.45
5.87

Unknown
Mitochondrial

31,609

9.03

Mitochondrial
inner
membrane

P55809

67
87
54

10
21
14

56,112

7.14

Mitochondrial
matrix

P04179

58

11

24,707

8.35

Mitochondrial
matrix

P21579

61
95

16
23

47,543

8.26

Synaptic
vesicles and
chromaffin
granules

O60225
P38646
P21912
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Table 3-10. (continued)
Q14956
58
5

62,603

6.17

Type I
membrane
protein

4601

Transmembrane
glycoprotein
NMB [Precursor]

4708

Tryptophan 5hydroxylase 1
Tubulin beta-2
chain

P17752

59

8

50,972

6.97

Mitochondrial

P07437

4.75

Unknown

Q99867

13
9
15
14

49,727

Tubulin beta-4q
chain
Ubiquinolcytochrome c
reductase ironsulfur subunit,
mitochondrial
[Precursor]
Ubiquinolcytochrome-c
reductase
complex core
protein 2,
mitochondrial
[Precursor]
Ubiquinolcytochrome-c
reductase
complex core
protein I,
mitochondrial
[Precursor]
Ubiquitin
carboxyl-terminal
hydrolase
isozyme L1
Vacuolar ATP
synthase catalytic
subunit A,
ubiquitous
isoform
Vacuolar ATP
synthase subunit
E

72
54
63
64

48,403

5.11

Unknown

P47985

83
104
52

17
34
11

29,633

8.55

Mitochondrial
inner
membrane

P22695

79

23

48,413

8.74

Mitochondrial
inner
membrane;
matrix side

P31930

105

22

52,585

5.94

Mitochondrial
inner
membrane

P09936

72

31

24,808

5.33

Cytoplasmic

P38606

186
67

17
14

68260

5.35

Mitochondrial

P36543

56

24

26,129

7.71

Unknown

0701
1404
1406
0402
5203
5206
5208

8602

3602

2303

2807
3805

7304

91

5302
5401
6401
8403
9401
5402
6403
6404
8402
2104
5802

Voltagedependent anionselective channel
protein 1
Voltagedependent anionselective channel
protein 2
Wilms' tumor 1associating
protein
Zinc finger
protein 169

Table 3-10. (continued)
P21796
61
19
88
30
102
31
77
25
139
30
P45880
83
22
59
20
62
17
84
23
Q15007
60
11
Q14929

54

11

30,623

8.63

Outer
membrane of
mitochondria
and plasma
membrane
Outer
mitochondrial
membrane

38,069

6.32

44,244

5.20

Nuclear

57,615

9.61

Nuclear
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Table 3-11. Proteins with significant alterations in AD brain (Bold proteins are encoded
by mitochondrial DNA)
Protein name
Calreticulin
[Precursor]
CTD small
phosphatase-like
protein
Delta-1-pyrroline-5carboxylate
dehydrogenase,
mitochondrial
[Precursor]
Fumarate hydratase,
mitochondrial
[Precursor]
Methylmalonatesemialdehyde
dehydrogenase
[acylating],
mitochondrial
[Precursor]
NADH-ubiquinone
oxidoreductase 13
kDa-B subunit
Peroxiredoxin 2
Prohibitin
Protein disulfideisomerase A3
[Precursor]
Ubiquinolcytochrome c
reductase iron-sulfur
subunit,
mitochondrial
[Precursor]

Accession
P
Number Value
P27797

0.03

Ratio of
expression
(AD/Control)
3.2

Subcellular
Location

O15194

0.02

0.58

Nuclear

P30038

0.01

0.18

Mitochondrial matrix

P07954

0.02

0.47

Mitochondrial and
cytoplasmic

Q02252

0.02

0.52

Mitochondrial

Q16718

0.01

0.71

mitochondrial inner
membrane

P32119
P35232
P30101

0.05
0.01
0.01

0.3
2.17
0.28

Cytoplasmic
cytoplasmic
Endoplasmic reticulum

P47985

0.03

0.47

mitochondrial inner
membrane

cytoplasmic

93

Figure 3-25. A representative 2-dimensional gel with 500 µg mitochondrial protein
loaded. 8 – 16 % SDS gel was stained by Sypro Ruby and the pI of the IPG strip was
from 3 to 10 (nonlinear).

94

Figure 3-26. A representative MALDI / TOF mass spectrum. Each peak represents a
unique peptide

95

Figure 3-27. The probability based Mowse score. Protein scores greater than 52 were
considered significant.

96

Figure 3-28. Proteins from the mitochondrial fraction classified by subcellular locations

97

Figure 3-29. Mitochondrial proteins classified by cellular function
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250
Control
AD

Intensity

200

150

100

50

0
VDAC

CNPase

Figure 3-30. Western blots of VDAC and CNPase. No significant difference was
observed in Western blots for both of proteins, which were consistent with what we got
from 2D gel analysis. * p < 0.05
Copyright © Jianquan Wang 2006
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CHAPTER FOUR

Discussion

4.1 Increased oxidative damage in nuclear and mitochondrial DNA in late stage
Alzheimer’s disease

Oxidative stress to neurons may play an important role in the pathogenesis of AD
(Marletta 1993; Lyras et al. 1997; Markesbery 1997; Marcus et al. 1998; Markesbery and
Lovell 1998; Markesbery and Carney 1999; Martin 1999; Lovell et al. 2000, 2001). This
increased oxidative damage includes elevated levels of oxidized DNA bases (Mecocci et
al. 1994; Gabbita et al. 1998; Wang et al. 2005; Wang et al. 2006), lipid peroxidation
(Lovell et al. 1995; Markesbery and Lovell 1998), and protein oxidation in AD brain
(Butterfield et al. 2003) and increased lipid oxidation in ventricular CSF (Lovell et al.
1997; Montine et al. 2001, 2002).

Because of the critical role of DNA in cellular

function, oxidative damage to DNA may be one of the most important factors in neuron
degeneration in AD. mtDNA may be more easily oxidized than nDNA due to its
proximity to free radical species and the lack of histone protection.
This study is the first to use GC/MS-SIM to quantify multiple oxidized base
adducts associated with mtDNA damage in LAD brain. Because of the large amounts of
tissue required to isolate sufficient amounts of mtDNA for GC/MS-SIM, our results
likely reflect a global measure of DNA oxidation from neurons and glia. Although there
is increased astrocytosis in the brain in AD, Nunomura et al. (1999) showed a significant
increase in 8-hydroxyguanine immunoreactivity in neuron cytoplasm in AD hippocampal
neurons, but little to no reactivity in glia, suggesting that DNA oxidation is
predominantly associated with neurons.
To verify that extracted mitochondria were pure, representative samples were
analyzed by electron microscopy and Western blot analysis.

Both showed the

mitochondria isolated were 95% pure after centrifugation through two Percoll gradients.
PCR amplification of APOE, a gene coded by nDNA, showed that mtDNA was not
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contaminated by nDNA. A previous study (Mecocci et al. 1994) demonstrated elevated
8-hydroxyguanisine in AD mtDNA; however, this is the first study to measure multiple
base adducts and provide a more comprehensive measure of DNA oxidation. Although 8hydroxyguanine is the predominate marker of oxidative damage, our results indicate
several other base adducts were significantly increased in nDNA and mtDNA of LAD
patients compared to age-matched controls subjects.
GC/MS-SIM is a highly selective and sensitive method that can monitor a wide
range of bases simultaneously and unequivocally in a single run. Detection limits can
approach 5 fmol (Halliwell and Dizdaroglu 1992), whereas the detection limit of HPLCECD is about 20 fmol. The major disadvantage in the use of GC/MS-SIM is the potential
for artifactual oxidation during hydrolysis and derivatization (Douki et al. 1996).
However, under proper processing, formic acid hydrolysis and derivatization do not
induce artifacts (Dizdaroglu 1998). In our study, we excluded oxygen during these two
steps, and used 8-hydroxyquinoline as an antioxidant to prevent artifactual DNA
oxidation during extraction.
During DNA isolation, Na2EDTA was added to complex trace metals that could
catalyze oxidation. Prolonged PMIs could also contribute to artifactual oxidation and, in
most other studies, tissue samples with PMIs longer than 6 hr were used. In contrast, we
used brain specimens with short PMI (2.9 ± 0.2 hr for control and 3.3 ± 0.2 hr for LAD).
Calculation of correlation coefficients between PMI and levels of oxidized bases showed
no significant correlation for any of the oxidized base adducts (r < 0.5).
In order to verify that phenol extraction does not induce artifactual oxidation, the
NaI 'salting out' method was used to isolate nDNA and mtDNA from representative
tissues. Our results show that levels of DNA oxidation from representative brain
specimens processed using the two methods are similar. Levels of 8-hydroxyguanine
showed no significant difference between these two methods, although there was a
decrease in fapyguanine and fapyadenine of nDNA and fapyadenine of mtDNA samples
and an increase in 5-hydroxycytosine of mtDNA using NaI precipitation.
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One concern in DNA isolation using phenol/chloroform extraction was the
artifactual oxidation caused during isolation. Comparison of levels of base adducts in
DNA isolated using either NaI precipitation or phenol/chloroform extraction suggests that
phenol/chloroform extraction did not lead to artifactual oxidation. Therefore, all DNA
samples used for statistical analyses in our studies were isolated using phenol/chloroform
extraction.
Our data show significantly increased oxidative DNA damage in LAD subjects
compared to age-matched controls with levels of damaged bases in mtDNA
approximately 10-fold those of nDNA (2.8 < ratio of mtDNA/nDNA < 23.8).
Comparison of mtDNA and nDNA oxidative damage for each oxidized base showed
statistically significantly increased oxidation in mtDNA for both LAD and control
subjects for all base adducts analyzed. There were no significant differences in the ratio
of mtDNA/nDNA oxidized bases between LAD and control subjects, which may be due
to variability in the degree of oxidation between mitochondria and nuclei in LAD and
aged control subjects.
In order to compare levels of oxidative damage in nDNA and mtDNA in the other
way, we list oxidative levels in terms of lesions/106 total DNA bases, ratio of
lesion/unmodified DNA base, percentage of lesions, and nmol/mg of DNA (Table 3-5).
Due to the big size difference between nuclear genome (3.3 billion bp) and mitochondrial
genome (16.6 kbp), the absolute value of oxidized bases in each nDNA molecule is much
larger than in mtDNA. However, mtDNA have much higher mutation rate which is more
important in protein synthesis (2.8 < ratio of mtDNA/nDNA < 23.8). nDNA has ~10%
protein coding genes, whereas 100% mtDNA are useful genes in protein synthesis.
Considering above two facts, mutations in mtDNA cause far worse consequences than
mutations in nDNA.
The absolute level of 8-hydroxyguanine is the highest of the damaged bases in
both control and LAD subjects, which is consistent with previous studies (Mecocci et al.
1993, 1994; Lyras et al. 1997; Gabbita et al. 1998; Birincioglu et al. 2003), suggesting
that guanine is the DNA base most vulnerable to oxidative damage (Aruoma et al. 1989;

102

Steenken 1989; Floyd et al. 1990; Halliwell and Dizdaroglu 1992; Gabbita et al. 1998;
Dizdaroglu et al. 2002; Birincioglu et al. 2003; Musiek et al. 2004). In nDNA and
mtDNA from temporal lobe, five of the six oxidized bases (except fapyguanine) were
increased significantly in LAD. In mtDNA from parietal lobe, statistically significant
increases

in

levels

of

8-hydroxyguanine,

fapyguanine,

5-hydroxyuracil,

5-

hydroxycytosine, and fapyadenine were observed.
For different DNA bases, the variation in levels of oxidation may be due to their
different structures and redox potentials (Steenken 1989). This is one reason why all
adducts are not elevated in the same proportion, even in the same brain region. Also it is
possible that a small variable amount of white matter was present in some specimens,
which might alter the cellular makeup of the specimens. Our results show that there is
more oxidative damage in neocortical regions in AD brain than cerebellum, which has
minimal pathologic changes in AD and is consistent with previous studies (Mecocci et al.
1994; Hensley et al. 1995; Lovell et al. 1995; Lyras et al. 1997; Gabbita et al. 1998). The
variation in levels of DNA damage in brain regions may be due to differences in trace
metals, antioxidant levels, and repair mechanisms (Xie et al. 1996; Cornett et al. 1998;
Lovell et al. 1998, 1999, 2002). The levels of oxidized bases per million DNA bases in
our study are consistent with previous studies using HPLC (Mecocci et al. 1993, 1994)
and GC/MS (Lyras et al. 1997; Dizdaroglu 1998; Dizdaroglu et al. 2002; Birincioglu et al.
2003).
High levels of free radical damage in mitochondria may cause impaired
mitochondrial function, which may result in cellular dysfunction in neurons. Previous
studies (Lustbader et al. 2004) demonstrated a link between Aβ and mitochondrial
toxicity through Aβ binding to alcohol dehydrogenase. This interaction in mitochondria
promotes increased ROS formation, mitochondrial dysfunction, and neuron death
(Wallace 1992; Markesbery 1997). Thus, it is possible that the increase in Aβ in AD
enhances mtDNA oxidation, which also might cause variable results from region to
region. Oxidative damage to DNA may accelerate protein crosslinking and aggregation,
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such as beta amyloid and tau protein (Dyrks et al. 1992, 1993; Butterfield et al. 1999;
Varadarajan et al. 2000; Butterfield 2003).
The current study shows that the neuron degeneration in AD may be associated
with oxidative damage to both nDNA and mtDNA, with more pronounced damage
accumulating in mtDNA. In contrast to nDNA that contains ~10% protein coding genes,
entire mtDNA encode 37 genes exclusively involved in respiratory chain. Accumulation
of mitochondrial mutations could lead to energy deficiencies and eventually neuron death
in the brain in AD.
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4.2 Increased oxidative damage in nuclear and mitochondrial DNA in Mild
Cognitive Impairment

This is the first study to quantify multiple oxidized DNA base adducts in MCI
brain. Although the DNA in this study was isolated from a mixture of glia and neurons,
previous immunohistochemical studies show that only neurons are immunopositive for 8hydroxyguanine (Hirai et al. 2001; Aliyev et al. 2005), suggesting that the levels of
oxidized bases which we measured represent neuronal DNA oxidation.
Our data showed significantly (p < 0.05) increased levels of all base adducts
analyzed in mtDNA compared with nDNA for both MCI and control subjects.
Comparison of MCI and control subjects shows significantly increased levels of oxidized
base adducts in MCI subjects compared with control subjects in several brain regions.
The absolute level of 8-hydroxyguanine was the highest among the five adducts analyzed,
which is consistent with previous studies of LAD brain (Mecocci et al. 1993, 1994; Lyras
et al. 1997; Gabbita et al. 1998; Birincioglu et al. 2003; Wang et al. 2005). Guanine is
particularly vulnerable to oxidation by hydroxyl radicals because of its high electron
density (Steenken 1989). Our data show significantly elevated 8-hydroxyguanine in
nDNA from MCI frontal and parietal lobe but not temporal lobe or cerebellum. These
data are consistent with our previous study of late-stage AD subjects that showed
significantly elevated 8-hydroxyguanine in frontal and parietal lobe DNA but not
temporal lobe (Wang et al. 2005).
In contrast to our study of LAD subjects that showed significantly elevated 8hydroxyguanine in mtDNA from parietal and temporal lobe, our current data show a
significant elevation in mtDNA from temporal lobe only. Our current data show no
significant differences in levels of fapyguanine in nDNA or mtDNA between MCI and
control subjects which is in contrast to our previous study of LAD subjects that showed a
significant elevation of fapyguanine in mtDNA from parietal lobe and cerebellum (Wang
et al. 2005).
Free radical attack of C8 of adenine leads to 8-hydroxyadenine radicals that result
in 8-hydroxyadenine and fapyadenine in the presence and absence of oxygen,
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respectively (Steenken 1989; Breen and Murphy 1995; Dizdaroglu et al. 2002). Our
results show significantly elevated 8-hydroxyadenine in nDNA from frontal, temporal
and parietal lobes and significant increases in fapyadenine in both nDNA and mtDNA
from frontal, temporal and parietal lobes of MCI subjects. The significant elevation of
fapyadenine raises the question of a hypoxic environment being present in MCI. Hypoxia
can also increase the risk of AD (Tatemichi et al. 1994; Kokmen et al. 1996; Higashide
et al. 2004; Smith et al. 2004). In a particular brain region, electrophilic free radicals have
different reaction rate constants with different bases (Steenken 1989) which may be one
reason why absolute levels of the five adducts studied here varied between brain regions
in the same subject.
Statistical analysis using two-way ANOVA showed that 8-hydroxyguanine,
fapyadenine and 5-hydroxycytosine were significantly elevated in mtDNA but not nDNA
from neocortical regions compared with cerebellum in MCI subjects. In controls there
were no significant differences in levels of any of the base adducts studied in mtDNA or
nDNA from neocortical regions compared with cerebellum. These observations are
consistent with minimal pathological changes in cerebellum in normal aging brain
(Mecocci et al. 1994; Hensley et al. 1995; Lovell et al. 1995; Lyras et al. 1997; Gabbita
et al. 1998) and with our previous studies of DNA adducts in LAD brain (Gabbita et al.
1998; Wang et al. 2005). Neocortex and cerebellum have different levels of trace metals,
antioxidants and DNA repair capacities (Xie et al. 1996; Cornett et al. 1998; Lovell et al.
1998, 1999, 2002; Dizdaroglu et al. 2002; Hashiguchi et al. 2004; Stuart et al. 2005)
which may contribute to the different yields and patterns of DNA modification observed
here.
Comparison of levels of oxidized bases and the presence of Apolipoprotein-E4
(APOE-4) alleles showed no significant differences in levels of oxidized bases between
subjects carrying an APOE-4 allele and subjects who carried no APOE-4 alleles (Table 36).
In this study, we used brain specimens with short post-mortem intervals
(3.0 ± 0.4 h for control subjects and 4.0 ± 0.9 h for MCI subjects), which is important
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because prolonged post-mortem interval may lead to artifactual oxidation. During DNA
isolation, Na2EDTA was added following homogenization to chelate trace metals that
may catalyze oxidative reactions (Xie et al. 1996; Cornett et al. 1998; Lovell et al. 1998,
1999, 2002). In addition, 8-hydroxyquinoline was added to phenol to prevent artifactual
oxidation during DNA extraction.
To limit the possibility of artifactual oxidation during processing of DNA for
GC/MS-SIM, tubes containing DNA samples were fully evacuated during formic acid
hydrolysis and N,O-bis(trimethylsilyl)trifluoroacetamide derivatization which was
previously shown to limit artifactual oxidation during DNA derivatization (Dizdaroglu
1998). Levels of oxidative damage that we measured are similar to previous studies of
DNA oxidation in AD brain using HPLC (Mecocci et al. 1993, 1994) and gas
chromatography/mass spectrometry (Lyras et al. 1997; Dizdaroglu 1998; Dizdaroglu et al.
2002; Birincioglu et al. 2003; Wang et al. 2005)
Compared with our previous study of LAD (Wang et al. 2005), these data show
that levels of oxidized bases, especially 8-hydroxyguanine, 8-hydroxyadenine and
fapyguanine, were not significantly different in MCI compared with LAD subjects.
These results suggest that both nDNA and mtDNA are oxidized early in the progression
of MCI to advanced AD. Due to the crucial role DNA plays in cells, high levels of
oxidation, particularly early in the progression of AD, may result in a decline of normal
cell function through altered transcription, changes in protein expression or cross-linking
with proteins. In all regions of both control and MCI subjects, there is significantly more
mtDNA damage than in nDNA (p < 0.02). mtDNA is more susceptible to oxidation
because of the proximity to ROS, lack of protective histones and relatively limited
antioxidant capacities. Repair of 8-hydroxyguanine through base excision repair (BER)
has been demonstrated in mitochondria (Stuart et al. 2005). Although there have been no
studies of BER in mitochondria from AD, MCI or aged control subjects, previous studies
showed decreased BER capacity in mitochondria of aged rats (Chen et al. 2002;
Englander et al. 2002). Our previous study of AD and control subjects showed decreased
BER in nuclei isolated from AD brain (Lovell et al. 2000b). However, we did not
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compare BER activity in mitochondria from AD subjects but would anticipate that
mitochondrial BER may be diminished consistent with decreased nuclear activity. It is
possible that the combination of diminished repair capacity and accumulated DNA
damage in nuclei and mitochondria may lead to neuron death (Wallace 1992; Hashiguchi
et al. 2004; Stuart et al. 2005).
In summary, our data show elevated levels of oxidized base adducts in MCI
compared with age-matched control subjects that are similar to levels observed in LAD
subjects, which suggests that the oxidative damage to nDNA and particularly mtDNA
occurs early in the course of AD and may contribute to the pathology of
neurodegeneration.
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4.3 Increased oxidative damage in nuclear DNA in APP/PS1 transgenic mice

This is the first study to quantify oxidized DNA base adducts in APP/PS1 mice
with GC/MS-SIM. Our results show significantly increased levels of 8-hydroxyguanine
in nDNA of 12 month old APP/PS1 mice compared to wild type mice. The absolute
level of 8-hydroxyguanine is consistently higher than 8-hydroxyadenine, which is
consistent with previous AD studies (Mecocci et al. 1993; Mecocci et al. 1994; Lyras et
al. 1997; Gabbita et al. 1998; Birincioglu et al. 2003; Wang et al. 2005; Wang et al. 2006).
Due to the electrophilic property, guanine is vulnerable to be oxidized by ROS. In the
oxidative condition, the oxidation is in favor of the production of 8-hydroxyguanine
(Steenken 1989a).

This significant elevation of the levels of 8-hydroxyguanine is

consistent with the previous studies which showed the early-onset increased Aβ
production in APP/PS1 transgenic mice (Borchelt et al. 1996; Duff et al. 1996; Borchelt
et al. 1997). The levels of oxidized base adducts are comparable to previous AD studies
using HPLC (Mecocci et al. 1993; Mecocci et al. 1994) and GC/MS (Lyras et al. 1997;
Dizdaroglu 1998; Dizdaroglu et al. 2002; Birincioglu et al. 2003; Wang et al. 2005;
Wang et al. 2006).
Our results also show a positive correlation between the amyloid plaque burden
and levels of 8-hydroxyguanine in APP/PS1 mice (r = 0.90). No positive correlation was
observed between amyloid plaque burden and levels of 8-hydroxyadenine.

Previous

studies suggest that Aβ may accelerate the generation of free radicals, which may
increase oxidative damage in cells (Hensley et al. 1994; Markesbery 1997; Butterfield
and Boyd-Kimball 2005).

Increasing evidence suggests that Aβ may cause

mitochondrial dysfunction and apoptosis, and that normal mitochondrial respiration is
diminished with Aβ and free radicals, such as nitric oxide (Casley et al. 2002; Reddy et al.
2004). Studies showed that PS1 alone did not induce amyloid pathology, while PS1
coexpressing with APP showed the early onset deposition of Aβ (Shen et al. 1997).
To avoid artifactual DNA oxidation during nDNA isolation and sample
preparation before GC injection, Na2EDTA was added during tissue homogenization, and
glass tubes were fully evacuated in the steps of formic acid hydrolysis and BSTFA
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derivatization (Dizdaroglu 1998); (Xie et al. 1996; Cornett et al. 1998; Lovell et al. 1998;
Lovell et al. 1999a; Lovell et al. 2002; Wang et al. 2005; Wang et al. 2006).
DNA oxidation may accumulate without efficient DNA repair ability. DNA
damage may result in decline in normal cell functions through blocking transcription,
changing protein expression, or cross-linking with proteins (Wallace 1992).

The

increased early-onset Aβ deposition accelerates the free radical production and results in
neuronal death because of the mitochondrial dysfunction (Reddy et al. 2004).
In summary, our data show significantly elevated 8-hydroxyguanine in APP/PS1
mice at the age of 12 month old, which is consistent with the increased Aβ production.
This mouse model may provide an insight to study the mechanism of neuron death and
pathology of AD.

110

4.4 Proteomic studies of mitochondria in Alzheimer’s disease

This study is a comprehensive survey of mitochondrial proteins in AD brain,
which

may

provide

more

information

about

mitochondrial

dysfunction

in

neurodegenerative diseases.
On each gel, ~650 protein spots were visualized with Sypro ruby staining. Sypro
ruby provided a wider dynamic range than silver staining and is more sensitive than
Coomassie Blue Staining (Berggren et al. 2000). On these gels, the majority of proteins
were mid-sized proteins (10 kDa < M.W. < 90kDa). This is consistent with previous
studies that showed middle range molecular weight proteins dominated the mitochondrial
proteome (Taylor et al. 2003).
Among 176 differentially expressed spots, ~66% were mitochondrial, which
represent 67 unique proteins. The remaining spots mainly consisted of proteins from
cytoplasm (13%), nuclei (3%), and ER (5%). ~11% of the identified proteins were
uncertain in localization.

The percentage of mitochondrial protein was higher than

previous mitochondrial studies (~40%) (Mootha et al. 2003; Fukada et al. 2004; Jiang et
al. 2005), consistent with our Western blot charactering mitochondrial fraction using Oct1 immunochemistry.
Based on different functions annotated by GeneBank and EXPASY, the 67
mitochondrial proteins were classified into 11 categories (Taylor et al. 2003). About half
of mitochondrial proteins were enzymes involved in redox, TCA cycles, and the
respiratory chain. Results showed that the enzymes involved in TCA cycle were mainly
in mitochondrial matrix which was consistent with a previous study (Wallace 1999). The
majority of enzymes function in respiratory chain and redox reactions and are located in
the inner membrane of mitochondria, where the main components of enzyme complexes
I-V are located (Wallace 1999). ~20% of the identified mitochondrial proteins were
involved in carbohydrate metabolism, lipid metabolism, nucleotide metabolism, and
glycolysis. 13% of the proteins identified were signaling proteins, mainly isoforms and
subunits of G protein, which function as modulators or transducers in various
transmembrane signaling systems (Gao et al. 1987). The targeting proteins identified
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were mainly heat shock proteins, which facilitate folding of imported proteins. Under
stress conditions, they may prevent misfolding and promote refolding of proteins (Venner
et al. 1990; Hansen et al. 2003). VDAC1 (porin) and VDAC2 were also identified, which
function to form channels allowing diffusion of small hydrophilic molecules in
mitochondrial membranes (Yu et al. 1995).
Due to the restrictions of 2D gel electrophoresis and staining methods, we can
only quantify and identify proteins with high expression levels.

67 mitochondrial

proteins out of ~2000 were identified, which represents a small percentage of total
mitochondrial proteins.

This may be the reason why we only see 2 out of 13

mitochondrial-encoded proteins in our study.
Student’s t-test was applied to analyze the protein expression changes.
abundance of 10 proteins was significantly altered.

The

They include 5 mitochondrial

proteins, 3 cytoplasmic proteins, 1 ER protein, and 1 nuclear protein. However, as no
commercial antibodies were available, we used rabbit anti-VDAC and rabbit anti-CNPase
for Western analysis. No significant difference was observed in Western blots for both
proteins, which were consistent with what we got from 2D gel analysis.
NADH-ubiquinone oxidoreductase 13 kDa-B subunit, a mitochondrial-encoded
subunit of complex I localized in the matrix side of the mitochondrial inner membrane,
was decreased significantly in LAD brain. The protein functions to transfer electrons
from NADH to the respiratory chain. In this process, ubiquinone is electron acceptor and
is reduced to ubiquinol (Pata et al. 1997; Tensing et al. 1999). Decreased expression of
NADH-ubiquinone oxidoreductase 13 kDa-B subunit in mitochondrial complexes may
reduce the capacity and efficiency of ATP synthesis in AD brain, which may cause
neuron death because of the energy deficiency.
Ubiquinol-cytochrome c reductase iron-sulfur subunit is also significantly
decreased in AD brain, and is one mitochondrial-encoded subunit of complex III, which
is located on the mitochondrial inner membrane. It is involved in the respiratory chain
which generates the electrochemical potential necessary to promote ATP synthesis
(Nishikimi et al. 1990; Grimwood et al. 2004). The electron transfer may be affected
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because of the lower expression of ubiquinol-cytochrome c reductase iron-sulfur subunit.
Lower electrochemical potentials may lead to ATP deficiencies for neurons in AD brain.
Two aldehyde dehydrogenases (Delta-1-pyrroline-5-carboxylate dehydrogenase and
Methylmalonate-semialdehyde dehydrogenase) were decreased in AD.
Delta-1-pyrroline-5-carboxylate dehydrogenase is located in the mitochondrial
matrix and catalyzes conversion of Delta-1-pyrroline-5-carboxylate to glutamate. It is an
interconnecting step between urea and TCA cycles.

The decreased expression was

consistent with previous studies of mental retardation, and AD (Hu et al. 1996; Li et al.
1997; Geraghty et al. 1998). Glutamate is the major excitatory neurotransmitter. Low
expression of delta-1-pyrroline-5-carboxylate may disturb glutamate transport in neurons.
Glutamate transporter alterations may affect the APP expression and calcium influx in
neuronal cells, which may induce neuronal damage and memory loss in AD brain
(Greenamyre et al. 1988; Li et al. 1997; Burbaeva et al. 2005).
Methylmalonate-semialdehyde dehydrogenase is an enzyme which catalyzes the
reaction of 2-methyl-3-oxopropanoate and NAD+ to propanoyl-CoA and NADH which is
used in ATP generation through the electron transport chain. It plays an important role in
valine and pyrimidine metabolism (Chambliss et al. 2000).
Fumarate hydratase is involved in the TCA cycle. It catalyzes the conversion of
fumarate to malate. Defects in fumarate hydratase may cause the fumarase deficiency
characterized by progressive encephalopathy, developmental delay, and cerebral atrophy.
It also acts as a tumor suppressor (Coughlin et al. 1998; Tomlinson et al. 2002).
Fumarase deficiency will cause the disorders of pyruvate metabolism and the oxygen –
dependent energy production (Pithukpakorn 2005). All the five enzymes discussed above
are associated with mitochondrial energy production. The decrease in these protein
expressions in AD brain may cause the energy deficiency leading to neuron cell death.
This study provides a proteome map of mitochondria in AD brain and several
proteins with altered expression. It also suggests that proteomic study in mitochondria
may provide an insight to study the pathogenesis of neuron degeneration in Alzheimer’s
disease.

Copyright © Jianquan Wang 2006
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CHAPTER FIVE

Conclusion

In summary, oxidative stress plays a crucial role in the development of AD.
Numerous studies show that the oxidation levels of DNA, protein, and lipids are
increased in Alzheimer’s disease. Mitochondria are the main energy source in eukaryotic
cells, and are the primary sites for endogenous ROS generation. Our studies suggest that
mitochondrial dysfunction might be involved in the process of neuron degeneration in
AD.
In the LAD study, our data showed significantly increased oxidative DNA
damage in LAD subjects compared to age-matched control subjects with levels of
damaged bases in mtDNA approximately 10-fold those of nDNA (2.8 < ratio of
mtDNA/nDNA < 23.8), which is consistent with the absence of histone protection and
low level of repair capacity for mtDNA. Results also showed that there was more
oxidative damage in neocortical regions in LAD brain than cerebellum, which is
consistent with the minimal pathologic changes in cerebellum in AD. The level of 8hydroxyguanine is constantly higher than other base adducts, consistent with the lowest
oxidation potential of guanine which is the most vulnerable to oxidative damage. This
study suggested that neuron degeneration in AD might be associated with oxidative
damage to both nDNA and mtDNA, especially mtDNA. Previous immunohistochemical
studies show that only neurons are immunopositive for 8-hydroxyguanine, suggesting
that the levels of oxidized bases which we measured represent neuronal DNA oxidation.
However, it is not clear whether these changes in LAD are primary or secondary to
neurodegeneration.
In order to see when the oxidation begins, we carried out a study of MCI and agematched control subjects.

Statistical analysis showed that 8-hydroxyguanine,

fapyadenine and 5-hydroxycytosine were significantly elevated in mtDNA but not nDNA
from neocortical regions compared with cerebellum in MCI subjects. Compared to the
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LAD study, the levels of oxidized base adducts in MCI are comparable to levels observed
in late-stage AD subjects. The significant elevation of fapyadenine raises the question of
a hypoxic environment being present in MCI. Previous studies showed that hypoxia can
also increase the risk of AD (Tatemichi et al. 1994; Kokmen et al. 1996; Smith et al.
2004). This study suggests that the DNA oxidation occurs early in the course of AD and
is less likely to be secondary to neurodegenerative alterations. It suggests that oxidative
damage to DNA might play an important role in AD progression.
Senile plaques are one of the main pathological hallmarks of AD. To study the
effect of Aβ plaques on DNA oxidation, nDNA from four age groups of APP/PS1
transgenic mice were analyzed.

The amyloid cascade hypothesis states that Aβ

processing and aggregation may contribute to the pathogenesis of AD. In the mouse
model coexpressing mutant APP and PS1, the deposition of senile plaques was
accelerated and the ratio of Aβ42/Aβ40 was increased in brain. Our results showed
significantly increased levels of oxidized 8-hydroxyguanine in nDNA of 12 month old
APP/PS1 mice compared to wild type and a positive correlation between amyloid plaque
counts and levels of 8-hydroxyguanine in APP/PS1 mice. Oxidative damage to DNA
may accelerate protein crosslinking and aggregation, such as beta amyloid and tau protein
(Dyrks et al. 1992; Dyrks et al. 1993; Mark et al. 1997; Varadarajan et al. 2000;
Butterfield and Castegna 2003). Aβ deposition in turn increases ROS production through
peptide interactions with redox-active trace metal ions (Huang et al. 1999). A previous
study (Lustbader et al. 2004) demonstrated a link between Aβ and mitochondrial toxicity
through Aβ binding to alcohol dehydrogenase, which causes increased ROS production.
There are ~2000 mitochondrial proteins encoded by both nDNA and mtDNA.
Based on the results from DNA studies, we expected to see altered expression of
mitochondrial proteins in AD brain. Our study provided a proteome map of mitochondria
in AD brain and showed 5 mitochondrial proteins related to energy production were
significantly altered in LAD. The down-regulation of mitochondrial proteins in AD brain
may affect ATP synthesis and cause the energy deficiency leading to neuronal death.
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In contrast to the nuclear genome that contains ~10% protein coding genes, the
entire mitochondrial genome is involved in coding for 37 genes including 13 proteins
exclusively involved in the respiratory chain, 22 tRNAs and 2 rRNAs for translation
machinery. Damage to mtDNA could be potentially more detrimental than alterations in
nDNA. All mitochondrial coded proteins are involved in oxidative phosphorylation and
ATP synthesis. Oxidative alterations of mtDNA could lead to synthesis of functionally
altered enzyme subunits, which in turn further augment ROS production.
DNA oxidation may accumulate without efficient DNA repair ability. DNA
damage may result in decline in normal cell functions through blocking transcription,
changing protein expression, or cross-linking with proteins. Aβ deposition accelerates
the free radical production and results in neuronal death because of the mitochondrial
dysfunction. Mutations in DNA lead to errors in protein biosynthesis, which especially
affects the high-energy consumptive neuronal cells.

The defects of mitochondrial

proteins may result from mutations of nDNA and mtDNA.

Alterations in nDNA-

encoded mitochondrial proteins that we observed may be due to mutations in nDNA, or
due to interruption during transportation from cytoplasm into mitochondria. Our results
show the decreased expression of 5 mitochondrial proteins. Two of them are encoded by
mtDNA, which accounts for 15% among the 13 mitochondrial-encoded proteins. Due to
the restriction of 2-D gel electrophoresis and gel staining methods, only proteins with
high expression levels could be identified and quantified. In our study, we identified 67
out of ~2000 mitochondrial proteins.

This may explain why only 2 mitochondrial

proteins were identified.
Oxidative damage to mitochondria, especially to respiratory enzymes, triggers
mitochondria to release more ROS from the respiratory chain, which would further
damage DNA and proteins.

This vicious circle eventually causes dysfunctional

mitochondria which would accumulate in non-dividing cells, such as neurons. Several
factors, including oxidative stress and calcium disruption, could induce apoptosis through
formation of a non-specific permeability transition pore that allows small molecular
solutes to swell the mitochondrial matrix, leading to rupture of outer membrane and
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release of several proapoptotic factors, including cytochrome c, resulting in activation of
cytosolic caspases and subsequent cell death. During mitochondrion-mediated apoptosis,
cytochrome c is released from intermembrane space and binds to apoptotic proteaseactivating factor 1 and caspase-9. This caspase complex activates downstream capases,
such as caspase 3, followed by further activation of capases and ultimately apoptosis.
Defective mitochondria can have catastrophic consequences for cells, not only due to loss
of ATP, but also due to the impairment of downstream functions, such as disruption of
calcium homeostasis. Accumulation of defective mitochondria may lead to neuronal cell
apoptosis.
What causes AD is not fully understood. Our results suggest ROS are involved,
although we do not know whether ROS production is a primary or secondary event.
Considerable evidence suggests there is increased oxidation of DNA, protein, lipid, and
RNA in AD brain. Neuronal death can be caused by many factors, such as enzyme
dysfunction, energy deficiency, etc. Removal of ROS seems like a potential way to slow
AD progression. Commonly used antioxidants have effects on slowing progression of
AD (Ames et al. 1993). The tolerance of neurons to oxidative stress is limited because
neurons are non-replicating cells and contain relatively low levels of antioxidants. Once
damaged, neurons are permanently dysfunctional or are committed to apoptosis.
Currently, definite AD only can be diagnosed at autopsy. Although memory and
recall tests are used to diagnose probable AD or predict individuals with high risk of AD,
considerable effort has been devoted to methods of early diagnosis. Our studies suggest
oxidative stress plays an important role in the development of AD. As the main energy
source of cell, mitochondria are the primary sites for endogenous ROS generation.
Neuron degeneration in AD may be associated with oxidative damage to DNA, especially
to mtDNA, which may lead to altered expression of proteins involved in ATP synthesis.
Our studies suggest that mitochondrial dysfunction might be involved in the process of
neuron degeneration in AD.

Copyright © Jianquan Wang 2006
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